---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence. Covers ARCHER II, ARCHER, AiiM OLE, ANX007-GLA-02, and ANX007-GLA-01. 214 evidence topics quoted from 51 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 ARCHER II

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Primary purpose: reduction of vision loss with monthly injections

> “The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with dry AMD with GA.”

Source: [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816)

<a id="topic-3.1.1.1-2"></a>

###### Main and secondary objectives in the EU trial record

> “To evaluate efficacy of intravitreal (IVT) injections of ANX007 on visual function and visual acuity”
> “To evaluate efficacy of IVT injections of ANX007 on secondary measures of visual function and visual acuity”
> “To compare the change in total loss of the ellipsoid zone (EZ) layer with IVT injections of ANX007 vs Sham control”
> “To assess the safety and tolerability of IVT injections of ANX007”
> “To assess patient reported outcomes”

Source: [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)

<a id="topic-3.1.1.1-3"></a>

###### Confirmation of the phase 2 ARCHER findings

> “Annexon’s registration program will initiate first with ARCHER II, a global sham-controlled trial designed to confirm the results from the Phase 2 ARCHER trial, and potentially expedite the path to regulatory approval in Europe”

Source: [Annexon Biosciences ARCHER II registrational program press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-outlines-global-registrational-program-anx007-geographic)

> “ARCHER II is designed to confirm the protection of visual acuity and visual structures demonstrated previously in our Phase 2 trial”

Source: [Annexon Biosciences ARCHER II enrollment press release (2025)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-announces-completion-enrollment-pivotal-phase-3-archer)

<a id="topic-3.1.1.1-4"></a>

###### Vision protection at Months 15 and 24

> “ARCHER II is designed to demonstrate clinically meaningful vision protection at Months 15 and 24.”

Source: [Annexon Biosciences third-quarter 2026 results press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-third-quarter-2026-financial-results-business)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Start of dosing in August 2024

> “today announced patient dosing was initiated in the global pivotal Phase 3 ARCHER II trial evaluating ANX007 for the treatment of geographic atrophy (GA)”

Source: [Annexon Biosciences ARCHER II update press release (2024)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-provides-update-archer-ii-global-registrational-program)

<a id="topic-3.1.1.2-2"></a>

###### Completion of enrollment in July 2025

> “today announced complete enrollment of the Phase 3 ARCHER II trial of vonaprument (formerly ANX007) for dry age-related macular degeneration (AMD) with geographic atrophy (GA)”

Source: [Annexon Biosciences ARCHER II enrollment press release (2025)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-announces-completion-enrollment-pivotal-phase-3-archer)

> “Enrollment was completed in July 2025.”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

<a id="topic-3.1.1.2-3"></a>

###### Regions of the study sites and of enrolled participants

> “Sites: North America, Europe, AUS, NZ”

Source: [Eichenbaum (2025)](https://annexonbio.com/wp-content/uploads/2025/07/Eichenbaum-ASRS-2025-Design-and-Rationale-ARCHER-II.pdf)

> “Participants from: North America (55%), Europe (43%), AUS/NZ (2%)”

Source: [Abbey (2026)](https://annexonbio.com/wp-content/uploads/2026/09/910_Friday_Abbey_Baseline-Characteristics-of-Participants-in-the-Phase-3-ARCHER-II-Trial-in-Dry-AMD-With-GA-FINAL-25Sept26.pdf)

<a id="topic-3.1.1.2-4"></a>

###### Expected timing of the Month 15 assessment and of study completion

> “An independent Data Monitoring Committee (DMC) will assess the ARCHER II single study Month 15 primary endpoint in the fourth quarter of 2026.”
> “ARCHER II completion, including Month 24 analyses, is expected in the third quarter of 2027.”

Source: [Annexon Biosciences third-quarter 2026 results press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-third-quarter-2026-financial-results-business)

<a id="topic-3.1.1.2-5"></a>

###### Registry dates and number of locations

> “Study Start (Actual) 2024-07-30”
> “Primary Completion (Estimated) 2027-07-31”
> “This study has 132 locations”

Source: [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Phase 3, randomized, double-masked, sham-controlled design

> “A Phase 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 (Vonaprument) Administered by Intravitreal Injection in Participants With Dry Age-Related Macular Degeneration With Geographic Atrophy”

Source: [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816)

> “ARCHER II is an ongoing global, pivotal, Phase 3 sham-controlled, double-masked trial of vonaprument in 659 patients with GA, a disease driven by early photoreceptor degeneration leading to vision loss.”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

<a id="topic-3.1.1.3-2"></a>

###### Randomization ratio and masking through Month 24

> “Treatment masked through 24 months”
> “Randomized 2:1”

Source: [Eichenbaum (2025)](https://annexonbio.com/wp-content/uploads/2025/07/Eichenbaum-ASRS-2025-Design-and-Rationale-ARCHER-II.pdf)

<a id="topic-3.1.1.3-3"></a>

###### Masked and unmasked study roles

> “At least 2 study physicians are required at each study site. A masked evaluating physician conducts routine study visits, which include safety assessments and eye examinations. An unmasked injecting physician performs all injections (ANX007 and Sham) and the immediate post-injection management.”
> “Treatment-revealing data, including PK and pharmacodynamics (PD) results, are not provided to the masked team until participant data have been cleaned (up to Month 24), the database has been locked, and the study is unmasked for the primary analysis.”

Source: [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)

<a id="topic-3.1.1.3-4"></a>

###### Study periods: screening, 24-month treatment, and Month 24 visit

> “The entire screening period (i.e., from the date of the first screening procedure until Day -1 [day prior to the first dose]), should not exceed 30 days for any given patient.”
> “Participants will visit the clinic each month during the 24-month treatment period for ANX007 or Sham administrations and safety assessments as detailed in the protocol”
> “All participants return to the clinic at Month 24/ET for”

Source: [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)

<a id="topic-3.1.1.3-5"></a>

###### Single protocol analyzed as two sub-studies for the United States filing

> “ARCHER II is a single protocol supporting a global registration path. The Phase 3 single study will be analyzed for EU filing and will be allocated into two pre-defined sub-studies for the U.S. filing and maintains strong statistical power at the sub-study level.”

Source: [Annexon Biosciences third-quarter 2026 results press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-third-quarter-2026-financial-results-business)

> “The single-study program will be analyzed as two sub-studies for the U.S. in accordance with the FDA’s two-trial recommendation.”

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

> “Single-study program analyzed as two sub-studies addresses FDA two-trial recommendation.”

Source: [Barakat (2025)](https://annexonbio.com/wp-content/uploads/2026/05/Barakat-FLORetina-2025-Design-and-Rationale-ARCHER-II.pdf)

<a id="topic-3.1.1.3-6"></a>

###### Original design announced in 2023: approximately 400 participants randomized 1:1 for 12 months

> “The Phase 3 ARCHER II trial is designed to enroll approximately 400 patients with GA secondary to age-related macular degeneration (AMD) who will be randomized 1:1 to receive a monthly dose of ANX007 or sham procedure. The primary endpoint will be the prevention of ≥15-letter loss of best corrected visual acuity (BCVA), which represents three lines on the standard ETDRS eye chart, in patients assessed through 12 months.”

Source: [Annexon Biosciences ARCHER II registrational program press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-outlines-global-registrational-program-anx007-geographic)

<a id="topic-3.1.1.3-7"></a>

###### Second head-to-head phase 3 trial against pegcetacoplan no longer planned

> “The single-study program will be analyzed as two sub-studies for the U.S. in accordance with the FDA’s two-trial recommendation. The primary endpoint of ARCHER II is prevention of ≥15-letter loss of BCVA, and an objective secondary structural measure is prevention of ellipsoid zone loss, both of which measures were met in the Phase 2 ARCHER trial. Accordingly, Annexon no longer plans to conduct a second injection-controlled head-to-head Phase 3 trial”

Source: [Annexon Biosciences fourth-quarter 2024 results press release (2025)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-fourth-quarter-and-year-end-2024-financial)

<a id="topic-3.1.1.3-8"></a>

###### Design informed by the phase 2 ARCHER trial

> “Learnings from the Phase 2 ARCHER study informed the ARCHER II design”

Source: [Eichenbaum (2025)](https://annexonbio.com/wp-content/uploads/2025/07/Eichenbaum-ASRS-2025-Design-and-Rationale-ARCHER-II.pdf); [Vujosevic (2025)](https://annexonbio.com/wp-content/uploads/2025/09/Vujosevic-EURetina-2025-Design-and-Rationale-ARCHER-II.pdf); [Sambhara (2026)](https://annexonbio.com/wp-content/uploads/2026/05/Sambhara-Hawaii-2026-Design-and-Rationale.pdf)

<a id="topic-3.1.1.3-9"></a>

###### Open-label extension offered after Month 24

> “Upon completion of Month 24, all patients have the option to receive monthly vonaprument treatment in the OLE study. The OLE study is designed to evaluate the long-term safety and benefit of vonaprument in patients with GA.”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Age, diagnosis, and study duration

> “Participant must be at least 50 years of age at the time of signing the informed consent.”
> “Able and willing to participate in a 24-month study with monthly visits.”
> “Diagnosis of dry AMD with GA as determined by the Investigator and confirmed by the independent Central Reading Center.”

Source: [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)

<a id="topic-3.1.1.4-2"></a>

###### Lesion size, multifocality, and junctional hyperautofluorescence on fundus autofluorescence

> “Well-demarcated GA with a total area (baseline lesion size) ≥2.5 mm2 and ≤ 17.5 mm2.”
> “If GA is multifocal, at least one focal lesion must measure ≥1.25 mm2 with the overall aggregate area of GA as specified above in 5a.”
> “Presence of hyper autofluorescence, any pattern, in the junctional zone of the GA. Absence of hyper autofluorescence (ie., pattern = none) is exclusionary.”

Source: [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)

<a id="topic-3.1.1.4-3"></a>

###### Best-corrected visual acuity of 45 to 83 letters

> “Normal luminance BCVA of 45 to 83 letters using ETDRS methodology(20/25 to 20/100 Snellen equivalent, inclusive).”

Source: [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)

> “Eyes with <45 ETDRS letters at baseline are excluded”
> “As in ARCHER, eyes with foveal and non-foveal lesions are included”

Source: [Eichenbaum (2025)](https://annexonbio.com/wp-content/uploads/2025/07/Eichenbaum-ASRS-2025-Design-and-Rationale-ARCHER-II.pdf); [Vujosevic (2025)](https://annexonbio.com/wp-content/uploads/2025/09/Vujosevic-EURetina-2025-Design-and-Rationale-ARCHER-II.pdf); [Sambhara (2026)](https://annexonbio.com/wp-content/uploads/2026/05/Sambhara-Hawaii-2026-Design-and-Rationale.pdf)

<a id="topic-3.1.1.4-4"></a>

###### Reason for excluding eyes with baseline acuity below 45 letters

> “Individuals with baseline BCVA <45 letters not enrolled in ARCHER II due to very low incidence of BCVA 15-letter loss in ARCHER”

Source: [Abbey (2026)](https://annexonbio.com/wp-content/uploads/2026/09/910_Friday_Abbey_Baseline-Characteristics-of-Participants-in-the-Phase-3-ARCHER-II-Trial-in-Dry-AMD-With-GA-FINAL-25Sept26.pdf)

<a id="topic-3.1.1.4-5"></a>

###### Fellow-eye choroidal neovascularization and fellow-eye GA treatment

> “history of CNV in fellow eye permitted”

Source: [Luo et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/Luo-ARVO-Poster-FINAL-27Apr26.pdf)

> “Fellow eyes treated with an approved anti-complement drug or other locally-administered treatment for GA that was initiated at least 4 weeks prior to randomization may continue treatment with no washout. Fellow eyes treated with an approved therapy for GA for fewer than 4 weeks should not be randomized in the study.”

Source: [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)

<a id="topic-3.1.1.4-6"></a>

###### Exclusion of GA from causes other than AMD

> “Geographic atrophy due to other causes than AMD such as Stargardt disease, cone-rod dystrophy, pathologic myopia, or toxic maculopathies (for example, plaquenil maculopathy) in either eye.”

Source: [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816)

<a id="topic-3.1.1.4-7"></a>

###### Exclusion of study-eye choroidal neovascularization, prior intravitreal or AMD treatment, and uveitis

> “Any evidence of CNV in the study eye”
> “History of any prior IVT treatment for any indication in the study eye.”
> “Any prior treatment for AMD in the study eye ( including investigational treatments, eg, pharmacological, surgical, radiation, thermotherapeutic, light therapy, or laser intervention), or systemic anti-GA or anti-complement treatment (including investigational treatments).”
> “History of idiopathic, autoimmune-associated, or other uveitis in either eye.”

Source: [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)

<a id="topic-3.1.1.4-8"></a>

###### Exclusion for myopia, uncontrolled glaucoma, and prior ocular surgery in the study eye

> “Spherical equivalent of -8.00 diopters (D) myopia or higher in the study eye.”
> “Uncontrolled glaucoma in the study eye (Intraocular pressure (IOP) >25 mmHg despite treatment with anti-glaucoma medication) or history of neovascular glaucoma.”
> “History of cataract surgery less than 3 months prior to dosing in the study eye”

Source: [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Vonaprument 5 mg monthly or sham monthly for 24 months

> “Participants will receive vonaprument IVT injections every month during the 24-month treatment period.”
> “Participants will receive Sham IVT injections every month during the 24-month treatment period.”

Source: [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816)

> “ANX007 once EM for 24 months (24 doses)”
> “Sham injection EM for 24 months”

Source: [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)

> “Vonaprument (ANX007) Monthly 5.0 mg/eye”

Source: [Eichenbaum (2025)](https://annexonbio.com/wp-content/uploads/2025/07/Eichenbaum-ASRS-2025-Design-and-Rationale-ARCHER-II.pdf)

<a id="topic-3.1.1.5-2"></a>

###### Injection volume

> “5 mg administered in 25 microliter dose”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-3.1.1.5-3"></a>

###### Sham procedure

> “Form and Route of Administration: to mimic IVT injection (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to stimulate the pressure of an injection).”

Source: [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816)

<a id="topic-3.1.1.5-4"></a>

###### Permitted concomitant supplements

> “NOTE: Oral supplements  (multivitamins/minerals, eg, AREDS vitamins) are permitted during the study.”

Source: [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Confirmed Best-corrected Visual Acuity Loss of 15 or More ETDRS Letters as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary endpoints: confirmed loss of 15 or more letters through Month 15 and through Month 24

> “Proportion of Participants Experiencing a Best Corrected Visual Acuity (BCVA) ≥15-letter Loss from Baseline Through Month 15 as Assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Any Two Consecutive Visits”
> “Proportion of Participants Experiencing a BCVA ≥15-letter Loss from Baseline Through Month 24 as Assessed by the ETDRS Chart at Any Two Consecutive Visits”

Source: [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816)

<a id="topic-3.1.1.6.1-2"></a>

###### Month 24 dual primary endpoint added in August 2026

> “today announced the addition of a Month 24 dual primary endpoint to complement the current Month 15 primary endpoint in its Phase 3 ARCHER II trial”
> “With a dual primary endpoint strategy, ARCHER II can achieve success in protecting against vision loss at either Month 15 or 24, which are independent efficacy timepoints.”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

> “In August 2026, we expanded the ARCHER II program to add a Month 24 dual primary endpoint, complementing the original Month 15 primary endpoint”

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

<a id="topic-3.1.1.6.1-3"></a>

###### Landmark analysis and alpha split between Month 15 and Month 24

> “Landmark analysis of proportion of patients with confirmed BCVA ≥15-Letter Loss at Month 15 or Month 24”
> “Alpha allocated between Month 15 (majority) and Month 24 for efficacy in label”

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b)

<a id="topic-3.1.1.6.1-4"></a>

###### Timing of the primary analysis in earlier disclosures

> “The primary analysis will occur between 12 and 18 months from dosing initiation based on the accumulation of target events (patients in the overall study experiencing BCVA ≥15-letter loss on consecutive visits).”

Source: [Annexon Biosciences ARCHER II update press release (2024)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-provides-update-archer-ii-global-registrational-program)

> “The primary analysis will occur at least 12 months from dosing initiation.”

Source: [Annexon Biosciences ARCHER II enrollment press release (2025)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-announces-completion-enrollment-pivotal-phase-3-archer)

> “Primary analysis: 12-15 months from dosing initiation”

Source: [Barakat (2025)](https://annexonbio.com/wp-content/uploads/2026/05/Barakat-FLORetina-2025-Design-and-Rationale-ARCHER-II.pdf)

<a id="topic-3.1.1.6.1-5"></a>

###### Secondary endpoints: time to confirmed loss, low-luminance acuity, ellipsoid zone, and safety

> “Time to Confirmed BCVA ≥15-letter Loss”
> “Proportion of Participants with Low-luminance BCVA (LLVA) ≥15-letter Loss”
> “Change from Baseline in Area of Total Loss of the Ellipsoid Zone (EZ) Layer”

Source: [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816)

> “Incidence and severity of ocular and systemic treatment-emergent adverse events (TEAEs) and adverse events of special interest (AESI)”

Source: [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)

<a id="topic-3.1.1.6.1-6"></a>

###### FDA alignment on the endpoint without a lesion-growth requirement

> “Annexon has gained alignment with the U.S. Food and Drug Administration (FDA) on a Phase 3 registration program that includes using, for the first-time, the prevention of ≥15-letter loss of best corrected visual acuity (BCVA) as the primary outcome measure”
> “Notably, the FDA has not required Annexon to study the slowing of lesion growth as measured by fundus autofluorescence (FAF), an anatomical endpoint used for the approval of other GA programs.”

Source: [Annexon Biosciences ARCHER II registrational program press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-outlines-global-registrational-program-anx007-geographic)

<a id="topic-3.1.1.6.1-7"></a>

###### FDA and EMA alignment on the endpoint

> “The ANX007 registrational program has received regulatory alignment with both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on key study elements, including on using, for the first-time in GA, best corrected visual acuity (BCVA) protection against ≥15-letter loss as the primary outcome measure (equivalent to three lines on a standardized eye chart).”

Source: [Annexon Biosciences ARCHER II update press release (2024)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-provides-update-archer-ii-global-registrational-program)

<a id="topic-3.1.1.6.1-8"></a>

###### Prior use of the endpoint in ophthalmology approvals

> “Best corrected visual acuity (BCVA) ≥15-letter loss represents three lines on the standard Early Treatment of Diabetic Retinopathy Study (ETDRS) eye chart. Proportion of patients experiencing BCVA ≥15-letter loss is a well-established functional endpoint that has served as the basis for numerous ophthalmology drug approvals by the FDA and European Medicines Agency.”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

<a id="topic-3.1.1.6.1-9"></a>

###### Functional primary endpoints of approved retinal products

| Indication and product | Functional primary endpoint |
| --- | --- |
| Wet AMD, Lucentis | “Trial 1 and 2: BCVA ≥15-letter change” |
| Wet AMD, Eylea and Eylea HD | “BCVA ≥15-letter change/Mean BCVA change” |
| Wet AMD, Vabysmo | “Mean BCVA change” |
| DME, Lucentis | “BCVA ≥15-letter change” |
| DME, Iluvien | “BCVA ≥15-letter change” |
| DME, Ozurdex | “BCVA ≥15-letter change” |
| GA | “No Approved Vision-Preserving Treatments” |

Source: [Luo et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/Luo-ARVO-Poster-FINAL-27Apr26.pdf)

<a id="topic-3.1.1.6.1-10"></a>

###### Clinical meaning of a loss of 15 or more letters

> “Decline of 15 or more in BCVA letter score is relevant in GA because the measure represents:”
> “a Snellen equivalent of 3 line or greater loss on a standardized ETDRS chart”
> “a doubling (or more) of the visual angle”
> “a 0.3 or more logMAR change”

Source: [Luo et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/Luo-ARVO-Poster-FINAL-27Apr26.pdf)

> “Loss of independence (e.g., inability to read, drive)”
> “Clinically relevant, stable endpoint when confirmed at two consecutive visits”

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b)

<a id="topic-3.1.1.6.1-11"></a>

###### Frequency of loss of 15 or more letters in prior GA datasets

> “>2000 eyes in the lampalizumab program”
> “~25% had BCVA ≥15-LL at 2 years”
> “Vision Loss varied with BL VA, ~30% ≥15-LL at 2 years”

Source: [Lally (2025)](https://annexonbio.com/wp-content/uploads/2025/09/Lally-Retina-Society-2025-Final.pdf)

> “Given that 31% of patients with GA and good vision demonstrate a 15-letter acuity loss over 24 months”

Source: [Csaky et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11162935/)

<a id="topic-3.1.1.6.1-12"></a>

###### Approved GA therapies: anatomic endpoint without demonstrated visual benefit

> “The approval of pegcetacoplan and avacincaptad was based on an anatomic endpoint of a reduction in the rate of GA expansion over time. However, functional data from two phase 3 clinical trials for each drug demonstrated no visual benefit to patients in the treatment groups.”
> “Although change in visual acuity is often the primary endpoint in clinical trials for new retinal drug applications, approval of a drug based solely on anatomic outcomes is not unprecedented.”

Source: [Csaky et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11162935/)

> “Assessing disease progression using functional parameters, such as visual acuity, is critical to determining therapeutic effect, as opposed to anatomical parameters alone”

Source: [Lally (2025)](https://annexonbio.com/wp-content/uploads/2025/09/Lally-Retina-Society-2025-Final.pdf)

<a id="topic-3.1.1.6.1-13"></a>

###### Basis in a prespecified analysis of the phase 2 ARCHER trial, whose primary endpoint was lesion growth

> “Loss of 15 or more ETDRS letters as measured by BCVA was a prespecified analysis in ARCHER”
> “6.2% greater reduction in rate of change in retinal pigment epithelium (RPE) loss from baseline with vonaprument treatment at 12 months – did not reach statistical significance (primary)”

Source: [Luo et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/Luo-ARVO-Poster-FINAL-27Apr26.pdf)

<a id="topic-3.1.1.6.1-14"></a>

###### Enrichment of the ARCHER II population and expected event rate

> “ARCHER BCVA ≥15-letter loss incidence rate consistent with larger prior datasets”
> “Enrichment strategy in ARCHER II likely increases BCVA ≥15-letter loss incidence rate”

Source: [Luo et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/Luo-ARVO-Poster-FINAL-27Apr26.pdf)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Planned enrollment of approximately 630 participants

> “In ARCHER II, ANX007 will be compared to sham control in a well-powered study with a robust safety database that is expected to enroll approximately 630 patients.”

Source: [Annexon Biosciences ARCHER II update press release (2024)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-provides-update-archer-ii-global-registrational-program)

<a id="topic-3.1.1.7.1-2"></a>

###### Enrollment of 659 participants

> “Expedited Enrollment Surpassing 630 Targeted Participants Underscores the Strong Demand for a Therapy Focused on Vision Preservation”

Source: [Annexon Biosciences ARCHER II enrollment press release (2025)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-announces-completion-enrollment-pivotal-phase-3-archer)

> “N = 659”
> “Randomized 2:1”

Source: [Abbey (2026)](https://annexonbio.com/wp-content/uploads/2026/09/910_Friday_Abbey_Baseline-Characteristics-of-Participants-in-the-Phase-3-ARCHER-II-Trial-in-Dry-AMD-With-GA-FINAL-25Sept26.pdf)

<a id="topic-3.1.1.7.1-3"></a>

###### Statistical power and sub-study size

> “Over-enrolled (n=659), powered to >90%”
> “Higher patient retention increased power to >90%”
> “Powered to show positive treatment effect at Month 15 or Month 24”
> “Larger sample size (N=659; n~330/substudy)”
> “Prior GA trials1 informed masked event rate projections, which have held during study”

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b)

> “Enrollment (Actual) 659”

Source: [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816)

<a id="topic-3.1.1.7.1-4"></a>

###### Number analyzed

No evidence found.

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Single study for the EU filing and two sub-studies of about 330 participants each for the United States filing

> “Single protocol for EU filing”
> “Single protocol analyzed as 2 sub-studies for US filing (powered at sub-study level)”
> “ARCHER IIa”
> “ARCHER IIb”
> “N~330”

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b)

<a id="topic-3.1.1.7.2-2"></a>

###### Sequence of the single-study and sub-study analyses

> “If the DMC recommends that the endpoint has been met, the DMC will evaluate the two pre-specified sub-studies, with results anticipated in the first quarter of 2027. Alternatively, the DMC may recommend continuing the trial through the Month 24 primary endpoint analysis.”

Source: [Annexon Biosciences third-quarter 2026 results press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-third-quarter-2026-financial-results-business)

> “ARCHER II is a single protocol that will also be analyzed as two sub-studies after meeting the primary endpoint.”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

<a id="topic-3.1.1.7.2-3"></a>

###### Follow-up of participants who discontinue treatment

> “Participants who discontinue from the treatment prior to completing the assigned treatment regimen will continue in the study and return to the clinic for follow-up assessments as scheduled”

Source: [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)

<a id="topic-3.1.1.7.2-4"></a>

###### Definitions of efficacy and safety analysis populations

No evidence found.

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Retention of 90% with at least 15 months of treatment

> “All eligible patients have received at least 15 months of treatment with patient retention at 90%, and masked vision-loss events have tracked closely with projections.”

Source: [Annexon Biosciences third-quarter 2026 results press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-third-quarter-2026-financial-results-business)

<a id="topic-3.1.1.8.1-2"></a>

###### Discontinuation below 10% and compliance above 95% as of August 2026

> “In the ongoing global, double-masked Phase 3 ARCHER II trial, all eligible patients have received at least 12 months of treatment, with masked event accrual in line with projections. The study retains strong statistical power and continues to be well-executed with a low discontinuation rate (<10%) and high compliance (>95%)”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

<a id="topic-3.1.1.8.1-3"></a>

###### Disposition by treatment arm

No evidence found.

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Demographic and structural characteristics compared with ARCHER

| Characteristic | ARCHER (N = 270) | ARCHER II (N = 659) |
| --- | --- | --- |
| Age, mean (SD) | “80.0 (8.2)” | “78.4 (8.0)” |
| Female | “61.5%” | “63.0%” |
| GA lesion size (mm2), mean (SD) | “7.36 (4.01)” | “7.23 (3.49)” |
| GA lesion location, subfoveal | “51.9%” | “54.8%” |
| Total EZ loss, mm2 (% of total area lost) | “12.7 (35.3%)” | “12.3 (34.3%)” |

Source: [Abbey (2026)](https://annexonbio.com/wp-content/uploads/2026/09/910_Friday_Abbey_Baseline-Characteristics-of-Participants-in-the-Phase-3-ARCHER-II-Trial-in-Dry-AMD-With-GA-FINAL-25Sept26.pdf); [Gallego-Pinazo (2026)](https://annexonbio.com/wp-content/uploads/2026/10/Gallego-Pinazo-Euretina.pdf)

<a id="topic-3.1.1.8.2-2"></a>

###### Visual acuity characteristics compared with ARCHER

| Characteristic | ARCHER (N = 270) | ARCHER II (N = 659) |
| --- | --- | --- |
| Mean BCVA (SD), letters | “58.4 (16.2)” | “65.8 (10.5)” |
| Baseline BCVA below 45 letters | “23.3%” | “0.0%” |
| Mean LLVA (SD), letters | “33.0 (16.9)” | “38.3 (17.2)” |
| Mean LLVD (SD), letters | “25.7 (16.9)” | “27.6 (15.6)” |
| LLVD below 30 letters | “62.4%” | “60.7%” |

Source: [Abbey (2026)](https://annexonbio.com/wp-content/uploads/2026/09/910_Friday_Abbey_Baseline-Characteristics-of-Participants-in-the-Phase-3-ARCHER-II-Trial-in-Dry-AMD-With-GA-FINAL-25Sept26.pdf); [Gallego-Pinazo (2026)](https://annexonbio.com/wp-content/uploads/2026/10/Gallego-Pinazo-Euretina.pdf)

<a id="topic-3.1.1.8.2-3"></a>

###### Proportions with foveal lesions and with low-luminance deficit below 30 letters

> “Foveal lesions at baseline: more than 50% of the study population”
> “Baseline LLVD < 30: more than 60% of the study population”

Source: [Abbey (2026)](https://annexonbio.com/wp-content/uploads/2026/09/910_Friday_Abbey_Baseline-Characteristics-of-Participants-in-the-Phase-3-ARCHER-II-Trial-in-Dry-AMD-With-GA-FINAL-25Sept26.pdf); [Gallego-Pinazo (2026)](https://annexonbio.com/wp-content/uploads/2026/10/Gallego-Pinazo-Euretina.pdf)

<a id="topic-3.1.1.8.2-4"></a>

###### Baseline characteristics by treatment arm

No evidence found.

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

No evidence found.

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary: design features and absence of results

As of November 15, 2026, no efficacy or safety result of ARCHER II has been released; the sponsor expects the independent Data Monitoring Committee assessment of the Month 15 primary endpoint in the fourth quarter of 2026, sub-study results in the first quarter of 2027 if the endpoint is met, and study completion with the Month 24 analyses in the third quarter of 2027. The only disclosed trial-level data are pooled, masked baseline characteristics of 659 participants and sponsor statements on retention (90%), discontinuation (below 10%), and compliance (above 95%); baseline data by arm and the numbers analyzed have not been published.

The design has changed since it was first announced. In December 2023 the trial was planned with approximately 400 participants randomized 1:1 and a primary endpoint assessed through 12 months; the enrolled trial randomized 659 participants 2:1 to monthly vonaprument 5 mg or sham. The timing of the primary analysis was described as 12 to 18 months from dosing initiation in 2024, at least 12 months in July 2025, 12 to 15 months in December 2025, and Month 15 in 2026. A Month 24 dual primary endpoint was added in August 2026 while masked follow-up was ongoing, with alpha allocated between the two timepoints (the majority to Month 15); the sponsor's Form 10-Q states that there is no assurance regulators will accept the amended dual primary endpoint design.

For the U.S. filing, the single protocol is divided into two pre-defined sub-studies of about 330 participants each to address the FDA two-trial recommendation, so the replication rests on two subsets of one trial with a shared protocol and conduct. The sham comparator is an injection-free procedure, and the planned injection-controlled trial against pegcetacoplan (ARROW) was dropped in March 2025, so ARCHER II will provide no comparison with an approved GA therapy. The endpoint rationale rests on the phase 2 ARCHER trial, in which the 15-letter loss analysis was prespecified while the primary lesion-growth endpoint “did not reach statistical significance”. Eligibility excludes eyes with baseline BCVA below 45 letters, which the sponsor states was chosen because few such eyes had 15-letter loss events in ARCHER; results will therefore not describe eyes with lower baseline acuity. Patient-reported outcomes are listed as a secondary objective in the EU record, and no instrument has been named.

Source: [Annexon Biosciences third-quarter 2026 results press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-third-quarter-2026-financial-results-business); [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy); [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm); [Annexon Biosciences ARCHER II registrational program press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-outlines-global-registrational-program-anx007-geographic); [Annexon Biosciences ARCHER II update press release (2024)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-provides-update-archer-ii-global-registrational-program); [Annexon Biosciences ARCHER II enrollment press release (2025)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-announces-completion-enrollment-pivotal-phase-3-archer); [Barakat (2025)](https://annexonbio.com/wp-content/uploads/2026/05/Barakat-FLORetina-2025-Design-and-Rationale-ARCHER-II.pdf); [Annexon Biosciences fourth-quarter 2024 results press release (2025)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-reports-fourth-quarter-and-year-end-2024-financial); [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b); [Abbey (2026)](https://annexonbio.com/wp-content/uploads/2026/09/910_Friday_Abbey_Baseline-Characteristics-of-Participants-in-the-Phase-3-ARCHER-II-Trial-in-Dry-AMD-With-GA-FINAL-25Sept26.pdf); [Luo et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/Luo-ARVO-Poster-FINAL-27Apr26.pdf); [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816); [EU CTIS 2024-515022-88-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-515022-88-00)

<a id="topic-3.1.1.9-2"></a>

###### Regulatory acceptance of the amended dual primary endpoint design

> “There can be no assurance that the FDA and comparable regulatory authorities will accept the data from our Phase 3 program, including the amended dual primary endpoint design or the OLE study, or that such data will be determined sufficient to support approval.”
> “Under the dual primary endpoint design, ARCHER II may achieve statistical success at either the Month 15 or Month 24 timepoint. However, there is no assurance that either timepoint will show a statistically significant treatment effect, that the FDA, EMA or other regulators will agree that success at one timepoint is sufficient to support approval, or that the design amendment itself will not require additional discussion, data or time to align with regulators.”

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

<a id="topic-3.1.1.9-3"></a>

###### Longer timeline from the added Month 24 endpoint and extension study

> “Our timeline and costs for ARCHER II could be substantially longer and larger than we initially planned, including as a result of the recently added Month 24 primary endpoint and OLE study, which extend the trial's duration and increase its complexity.”

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

<a id="topic-3.1.1.9-4"></a>

###### Data Monitoring Committee futility assessment

> “Futility – assessed by Data Monitoring Committee”

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b)

<a id="heading-3.1.2"></a>

#### 3.1.2 ARCHER

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Registered objective: effect of intravitreal ANX007 on GA lesion growth rate

> “This study is being conducted in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) to determine if intravitreal (IVT) injections of ANX007 reduce GA lesion growth rate.”
> “The results will be used to guide further development of ANX007 in participants with geographic atrophy.”
> “A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Masked, 4-Arm, Sham-Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) - The ARCHER Study”

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-3.1.2.1-2"></a>

###### Objective stated at trial initiation

> “The randomized, multi-center, double-masked Phase 2 trial is designed to evaluate the efficacy and safety of ANX007 in reducing the area of GA as evaluated by fundus autofluorescence (FAF) in patients with GA.”

Source: [Annexon Biosciences ARCHER initiation press release (2021)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-advances-classical-complement-platform-initiation-global)

<a id="topic-3.1.2.1-3"></a>

###### Objective stated with the topline results

> “ARCHER is a randomized, multi-center, double-masked, sham-controlled Phase 2 clinical trial comparing the safety and efficacy of ANX007 in patients with GA secondary to AMD.”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Registered study dates

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2021-02-26” |
| Primary completion (actual) | “2023-03-28” |
| Study completion (actual) | “2023-09-13” |

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-3.1.2.2-2"></a>

###### Study site countries

| Country | Example site location in the registry record |
| --- | --- |
| United States | “Boston, Massachusetts, United States” |
| Australia | “Adelaide, South Australia, Australia” |
| New Zealand | “Wellington, New Zealand” |

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-3.1.2.2-3"></a>

###### Share of participants enrolled in the United States

> “Ninety-six percent of patients enrolled were from the United States.”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

<a id="topic-3.1.2.2-4"></a>

###### First participant dosed: March 2021

> “March 1, 2021”
> “announced that patient dosing has begun in its Phase 2 ARCHER study of its anti-C1q therapy, ANX007, to treat Geographic Atrophy (GA)”

Source: [Annexon Biosciences ARCHER initiation press release (2021)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-advances-classical-complement-platform-initiation-global)

<a id="topic-3.1.2.2-5"></a>

###### Enrollment completed: April 2022

> “April 07, 2022”
> “today announced the completion of enrollment in the Phase 2 ARCHER trial evaluating its anti-C1q candidate, ANX007, in patients with geographic atrophy (GA)”

Source: [Annexon Biosciences ARCHER enrollment press release (2022)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-biosciences-completes-enrollment-archer-phase-2-trial)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Registered design elements

| Design element | Registry record |
| --- | --- |
| Phase | “Phase 2” |
| Allocation | “Randomized” |
| Intervention model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Primary purpose | “Treatment” |

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-3.1.2.3-2"></a>

###### Randomized, double-masked, sham-controlled design with stratification

> “ARCHER is a randomized, multi-center, double-masked, sham-controlled Phase 2 clinical trial comparing the safety and efficacy of ANX007 in patients with GA secondary to AMD.”
> “The study enrolled a total of 270 patients, stratified by GA lesion size, location and choroidal neovascularization (CNV) in the fellow eye at the time of enrollment.”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

<a id="topic-3.1.2.3-3"></a>

###### Foveal and non-foveal lesions included

> “Randomized, double-masked”
> “Included foveal and non-foveal lesions”
> “Stratified for lesion location and lesion size”

Source: [Pearlman (2024)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-Pearlman-FINAL.pdf)

<a id="topic-3.1.2.3-4"></a>

###### Twelve-month treatment period followed by six months off treatment

> “12 months (n=270)”
> “END OF STUDY Month 18 Off-treatment (6 months)”

Source: [Pearlman (2024)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-Pearlman-FINAL.pdf)

> “The total duration of participation is expected to be approximately 19 months.”

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-3.1.2.3-5"></a>

###### Visit schedule

> “visits were monthly through Month 12 and then at Months 15 & 18”

Source: [Chakravarthy (2026)](https://annexonbio.com/wp-content/uploads/2026/10/Chakravarthy-Euretina.pdf)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Key inclusion criteria

| Criterion | Quoted registry text |
| --- | --- |
| Age | “50 Years and older” |
| Diagnosis | “Diagnosis of geographic atrophy of the macula secondary to age-related macular degeneration as determined by the Investigator and confirmed by the Central Reading Center.” |
| Lesion size | “Well-demarcated GA with a total area (baseline lesion size) ≥2.5 millimeter squared (mm^2)” |
| Multifocal lesions | “If GA is multifocal, at least 1 focal lesion must measure ≥1.25 mm^2 with the overall aggregate area of GA as specified above.” |
| Junctional zone autofluorescence | “Presence of hyper autofluorescence, any pattern, in the junctional zone of the GA. Absence of hyper autofluorescence (that is, pattern = none) is exclusionary.” |
| Lesion imaging | “The entire GA lesion must be completely visualized on the macula centered image and must be able to be imaged in its entirety and not contiguous with any peripapillary atrophy.” |
| Visual acuity | “Normal luminance BCVA of 24 to 83 letters, inclusive, using ETDRS charts (20/25 to 20/320 Snellen equivalent, inclusive).” |

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-3.1.2.4-2"></a>

###### Key exclusion criteria

| Criterion | Quoted registry text |
| --- | --- |
| Other causes of atrophy | “Geographic atrophy due to other causes than AMD such as Stargardt disease, cone-rod dystrophy, pathologic myopia, or toxic maculopathies (for example, plaquenil maculopathy) in either eye.” |
| Choroidal neovascularization | “Any evidence of choroidal neovascularization (CNV) in the study eye” |
| Myopia | “Spherical equivalent of -8.00 diopters (D) myopia or higher in the study eye.” |
| Glaucoma | “Uncontrolled glaucoma in the study eye (Intraocular pressure [IOP] >25 mmHg despite treatment with anti- glaucoma medication) or history of neovascular glaucoma.” |
| Prior ocular surgery | “History of glaucoma filtration surgery, minimally-invasive glaucoma surgery involving an implant, or vitrectomy surgery, or other procedure in the study eye that could affect drug distribution and/or clearance.” |
| Prior intravitreal treatment | “History of any prior IVT treatment for any indication in the study eye.” |
| Prior AMD treatment | “Any prior treatment for AMD in the study eye (for example, surgical, radiation, thermotherapeutic, or laser intervention), except oral supplements or minerals.” |

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-3.1.2.4-3"></a>

###### Enrollment of participants at high risk of progression

> “A randomized, controlled Phase 2 trial in GA patients who are at a high risk of progression is ongoing, and we anticipate reporting data from this trial in 2023.”

Source: [Annexon Biosciences Form 10-K (2021)](https://www.sec.gov/Archives/edgar/data/1528115/000156459021015262/annx-10k_20201231.htm)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Registered arms and interventions

| Arm | Quoted registry description |
| --- | --- |
| ANX007 Group 1, experimental | “ANX007 administered every month” |
| ANX007 Group 2, experimental | “ANX007 administered every other month” |
| Sham Group 3, sham comparator | “Sham injection administered every month” |
| Sham Group 4, sham comparator | “Sham injection administered every other month” |
| ANX007 formulation and route | “Form: solution for injection; Route of Administration: IVT” |
| Sham procedure | “Form and Route of Administration: pressure to mimic IVT injection” |

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-3.1.2.5-2"></a>

###### Dose, schedule, and randomized arms

> “Patients were randomized to receive an intravitreal dose of 5mg ANX007 monthly (n=89), 5mg ANX007 every other month (n=92) or sham monthly or every other month (pooled n=89) for a treatment period of 12 months, followed by a six-month off-treatment period.”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

<a id="topic-3.1.2.5-3"></a>

###### Injection volume in phase 2

> “Dosing: 5 mg / 100 microliters in Ph2”

Source: [EURETINA Congress (2024)](https://annexonbio.com/wp-content/uploads/2024/09/Euretina-symposium.pdf)

<a id="topic-3.1.2.5-4"></a>

###### Dosing schedules planned at trial initiation

> “Monthly and every other month dosing schedules will be evaluated.”

Source: [Annexon Biosciences ARCHER initiation press release (2021)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-advances-classical-complement-platform-initiation-global)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Rate of Change in Geographic Atrophy Lesion Area by Fundus Autofluorescence as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Primary endpoint definition: GA lesion area slope by FAF through Month 12

> “Rate of Change (Slope) From Baseline to Month 12 in GA Lesion Area”
> “GA lesion area was assessed by fundus autofluorescence (FAF) imaging, by an independent central reading center for GA lesion area.”

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

> “The primary outcome measure of the study was the rate of change in GA lesion growth (slope) from baseline as measured by fundus autofluorescence through 12 months for the study eye.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-3.1.2.6.1-2"></a>

###### Sponsor rationale at trial start: natural history data and enrichment for fast progressors

> “Prior natural history data similar to that found in other recent large Phase 3 trials may provide a wealth of natural history data from nearly 2,000 patients on how to successfully enrich fast progressors of GA to enable an efficacy read-out within a one-year time period.”
> “The Phase 2 trial is designed to evaluate clinical effect on slowing of GA lesion growth, leveraging the natural history data and patient selection criteria of prior GA trials.”

Source: [Annexon Biosciences Form 10-K (2021)](https://www.sec.gov/Archives/edgar/data/1528115/000156459021015262/annx-10k_20201231.htm)

<a id="topic-3.1.2.6.1-3"></a>

###### Non-foveal lesions as a risk factor for faster lesion growth

> “Patients will be stratified by lesion location, with nearly half of enrolled participants having non-foveal lesions, a risk factor for more rapid progression.”
> “With nearly half of patients enrolled having non-foveal lesions, the ARCHER trial is designed to evaluate slowing of GA lesion growth in both patients who are at risk for faster progression and in the overall patient population.”

Source: [Annexon Biosciences ARCHER enrollment press release (2022)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-biosciences-completes-enrollment-archer-phase-2-trial)

<a id="topic-3.1.2.6.1-4"></a>

###### Regulatory acceptance of GA expansion measured by FAF

> “After extensive discussions, the FDA agreed that an acceptable clinical endpoint for GA could be the rate or extent of anatomic progression of GA in treatment and placebo groups.”
> “Fundus autofluorescence (FAF) imaging is the standard metric used by the FDA for assessing GA expansion.”
> “However, the relationship between function and altered autofluorescence at the GA border is still not clear.”

Source: [Csaky et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11162935/)

<a id="topic-3.1.2.6.1-5"></a>

###### Sponsor view after the readout: FAF measures the retinal pigment epithelium

> “Lesion growth is measured by fundus autofluorescence (FAF). FAF measures retinal pigment epithelial (RPE) cells under photoreceptors, not photoreceptor cells themselves or their function.”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

> “FAF measures RPE loss/lesion growth, but not photoreceptor or synapse loss and correlates poorly w/ visual function”
> “PRIMARY BIOMARKER ENDPOINT”

Source: [Pearlman (2024)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-Pearlman-FINAL.pdf)

<a id="topic-3.1.2.6.1-6"></a>

###### Prespecified visual function endpoints

> “The study included multiple pre-specified visual function measures to assess the effects of vonaprument on vision: change from baseline in BCVA; change from baseline in low-luminance best corrected visual acuity; and change in baseline from low-luminance visual acuity deficit, or LLVD.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

> “PRESPECIFIED SECONDARY FUNCTIONAL ENDPOINTS”

Source: [Pearlman (2024)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-Pearlman-FINAL.pdf)

<a id="topic-3.1.2.6.1-7"></a>

###### Best corrected visual acuity: ETDRS letter score

> “BCVA was assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score on a test chart at a starting distance of 4 meters at each study visit. BCVA scores range from 0 to 100 letters with a higher score indicating a better vision.”

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-3.1.2.6.1-8"></a>

###### BCVA loss of 15 or more letters: definition and rationale

> “Number of Events With Confirmed ≥ 15-Letter Loss BCVA Decline”
> “≥15-letter loss observed for 2 consecutive visits”

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

> “In this study, loss was defined as loss of 15 BCVA letters or more on two consecutive visits, or a loss at the end of the 12-month treatment period.”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

> “BCVA ≥15-letter loss universally deemed clinically meaningful”

Source: [Pearlman (2024)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-Pearlman-FINAL.pdf)

<a id="topic-3.1.2.6.1-9"></a>

###### Low-luminance visual acuity and low-luminance deficit

> “Low-luminance visual acuity: LLVA is BCVA assessed in low light conditions.”
> “Low-luminance visual deficit: LLVD is the difference between BCVA and LLVA.”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

> “LL-VD will be derived by subtracting LL-BCVA from BCVA.”

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Participants enrolled

> “ARCHER is a randomized, multi-center, double-masked, placebo-controlled Phase 2 clinical trial that enrolled a total of 270 patients with GA.”

Source: [Annexon Biosciences ARCHER enrollment press release (2022)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-biosciences-completes-enrollment-archer-phase-2-trial)

| Enrollment type | Participants |
| --- | --- |
| Actual | “270” |

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-3.1.2.7.1-2"></a>

###### Participants analyzed by population and arm

| Population | ANX007 EM | ANX007 EOM | Sham |
| --- | --- | --- | --- |
| Baseline (ITT) | “89” | “92” | “89” |
| Primary endpoint (non-subfoveal at baseline) | “38” | “43” | “45” |
| LLVA and LLVD ≥15-letter loss events | “79” | “85” | “79” |
| Safety | “89” | “92” | “89” |

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

| Population | ANX007 pooled |
| --- | --- |
| Primary endpoint (non-subfoveal at baseline) | “81” |

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.7.1-3"></a>

###### Optical coherence tomography subpopulation

> “ARCHER study Heidelberg Spectralis OCT population with baseline OCT data (n = 193)”

Source: [Jaffe et al. (2024a)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-V1-Jaffe-FINAL-15Jul24.pdf)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Intent-to-treat and safety populations

> “Intent-to-Treat (ITT) population included all randomized participants.”
> “Safety population included all randomized participants who received at least one dose of study drug.”

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.7.2-2"></a>

###### Primary endpoint analysis population: non-subfoveal participants

> “Non-subfoveal participants at baseline from the ITT population (all randomized participants).”

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.7.2-3"></a>

###### Low-luminance event analyses: participants with a postbaseline measurement

> “Participants with at least 1 postbaseline LLVA measurement in the ITT population (all randomized participants).”
> “Participants with at least 1 postbaseline LLVD measurement in the ITT population (all randomized participants).”

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.7.2-4"></a>

###### Primary endpoint model: linear mixed effect model

> “A linear mixed effect (LME) model was used to analyze the rate of change from baseline to Month 12 GA lesion area (mm2) for all groups.”
> “The model included fixed effects of treatment, time point, treatment by time point interaction, baseline GA lesion area, baseline GA lesion area by timepoint interaction, and baseline lesion multifocality.”
> “The GA lesion area was analyzed as reported (that is, not transformed).”

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-3.1.2.7.2-5"></a>

###### Visual acuity analyses: chi-square test and MMRM in the ITT population

> “Nominal p-value from a Chi-square test in ITT population”
> “Mean, standard error (SE), and p-value based on MMRM adjusting for baseline lesion location, lesion focality, baseline GA lesion, and the baseline GA lesion by visit interaction.”

Source: [Pearlman (2024)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-Pearlman-FINAL.pdf)

<a id="topic-3.1.2.7.2-6"></a>

###### Optical coherence tomography analysis population

> “Heidelberg Spectralis OCT population with baseline OCT data, excludes patients with >98% atrophy at baseline”

Source: [Jaffe et al. (2024a)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-V1-Jaffe-FINAL-15Jul24.pdf)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Registry participant flow through the overall study

| Milestone or reason | ANX007 EM | ANX007 EOM | Sham |
| --- | --- | --- | --- |
| Started | “89” | “92” | “89” |
| Received at least 1 dose of study drug | “89” | “92” | “89” |
| Completed | “73” | “77” | “76” |
| Not completed | “16” | “15” | “13” |
| Adverse event | “4” | “7” | “3” |
| Death | “0” | “0” | “1” |
| Lost to follow-up | “2” | “2” | “1” |
| Other than specified | “1” | “0” | “1” |
| Physician decision | “1” | “0” | “1” |
| Protocol violation | “1” | “1” | “0” |
| Withdrawal by subject | “7” | “5” | “6” |

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.8.1-2"></a>

###### Counts reported per participant

> “number of participants regardless of which eye was evaluated”

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.8.1-3"></a>

###### Treatment discontinuation by arm

| Measure | Sham pooled | ANX007 EM | ANX007 EOM |
| --- | --- | --- | --- |
| Discontinued treatment | “10 (11.2%)” | “13 (14.6%)” | “11 (12.0%)” |

Source: [EURETINA Congress (2024)](https://annexonbio.com/wp-content/uploads/2024/09/Euretina-symposium.pdf)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Registry baseline characteristics, ITT population

| Characteristic | ANX007 EM | ANX007 EOM | Sham | Total |
| --- | --- | --- | --- | --- |
| Participants | “89” | “92” | “89” | “270” |
| Age, years, mean (SD) | “79.7(8.64)” | “80.5(8.53)” | “79.8(7.49)” | “80.0(8.22)” |
| Female, participants | “47” | “60” | “59” | “166” |
| Male, participants | “42” | “32” | “30” | “104” |
| Hispanic or Latino, participants | “1” | “2” | “3” | “6” |
| White, participants | “87” | “89” | “87” | “263” |
| Asian, participants | “1” | “2” | “2” | “5” |
| Study eye GA lesion size, mm², mean (SD) | “7.2789(3.96342)” | “7.5284(4.09946)” | “7.2802(3.98783)” | “7.3643(4.00505)” |
| BCVA, ETDRS letters, mean (SD) | “58.8(17.19)” | “57.9(15.30)” | “58.5(16.23)” | “58.4(16.19)” |
| LLVA, ETDRS letters, mean (SD) | “35.3(16.41)” | “29.6(15.72)” | “34.2(18.05)” | “33.0(16.86)” |
| LLVA and LLVD, participants analyzed | “87 participants” | “91 participants” | “85 participants” | “263 participants” |
| LLVD, ETDRS letters, mean (SD) | “23.5(16.08)” | “28.3(18.39)” | “25.0(15.70)” | “25.7(16.86)” |

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.8.2-2"></a>

###### Lesion location, lesion size category, fellow-eye CNV, and multifocality

| Characteristic | Sham pooled (N=89) | Vonaprument EM (N=89) | Vonaprument EOM (N=92) |
| --- | --- | --- | --- |
| Foveal lesion | “49.4%” | “57.3%” | “53.3%” |
| GA lesion < 7.5 mm² | “61.8%” | “58.4%” | “57.6%” |
| Fellow eye CNV | “22.5%” | “24.7%” | “17.4%” |
| Multifocality, n (%) | “65 (73.0%)” | “61 (68.5%)” | “67 (72.8%)” |

Source: [Lally (2025)](https://annexonbio.com/wp-content/uploads/2025/09/Lally-Retina-Society-2025-Final.pdf)

<a id="topic-3.1.2.8.2-3"></a>

###### Company summary of baseline characteristics

> “Patients were nearly equally split between foveal (49.4% to 57.3%) and non-foveal groups, had an average age of 80 years and were balanced between female and male.”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

> “Patients had an average age of 80 years and, importantly, were well balanced for baseline visual acuity (BCVA between 58.3 and 58.5).”

Source: [Annexon Biosciences ASRS 2023 press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-presents-archer-trial-results-asrs-2023-highlighting)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Primary endpoint: rate of change in geographic atrophy lesion area through month 12, registry results

| Measure | ANX007 EM | ANX007 EOM | ANX007 Pooled | Sham |
| --- | --- | --- | --- | --- |
| Participants analyzed | “38” | “43” | “81” | “45” |
| Rate of change (slope), mean (SE), mm²/year | “1.9902(0.36343)” | “2.1575(0.34824)” | “2.0837(0.30177)” | “1.9019(0.34239)” |
| Change from baseline to month 12, least squares mean (SE), mm² | “2.3547(0.26452)” | “2.5782(0.24317)” | “2.4835(0.18003)” | “2.3170(0.23142)” |

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

> “Non-subfoveal participants at baseline from the ITT population (all randomized participants).”
> “A linear mixed effect (LME) model was used to analyze the rate of change from baseline to Month 12 GA lesion area (mm2) for all groups.”

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.8.3-2"></a>

###### Primary endpoint: company-reported reduction in lesion growth

> “The primary endpoint of mean rate of change (slope) in GA lesion area compared to sham at 12 months did not reach statistical significance. A 6.2% reduction in lesion growth was observed in monthly treatment group (p=0.526), a 1.3% reduction was observed in the every-other-month treatment group (p-value=0.896) and a 3.7% reduction was observed in the pooled patient population (p-value=0.673).”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

<a id="topic-3.1.2.8.3-3"></a>

###### Lesion growth by study period: additional analysis

> “While the primary endpoint of mean rate of change (slope) in GA lesion area compared to sham at 12 months did not reach statistical significance in the ARCHER trial, additional analyses showed that ANX007’s effect on lesion size showed a trend toward greater effect in the second six months of study for both treatment groups, suggesting that ANX007’s impact on lesion growth may increase with time.”

Source: [Annexon Biosciences ASRS 2023 press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-presents-archer-trial-results-asrs-2023-highlighting)

> “No significant reduction at month 12, but effects increased over 2nd half of study”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-3.1.2.8.3-4"></a>

###### Confirmed BCVA ≥15-letter loss: registry event counts, secondary outcome

| Measure | ANX007 EM | ANX007 EOM | Sham |
| --- | --- | --- | --- |
| Participants analyzed | “89” | “92” | “89” |
| Number of events with confirmed ≥15-letter loss | “4” | “8” | “15” |

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

> “Confirmed ETDRS BCVA ≥15-letter loss was deﬁned as ≥15-letter loss observed for 2 consecutive visits.”

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.8.3-5"></a>

###### Confirmed BCVA ≥15-letter loss: topline company counts and event definition

> “In this study, loss was defined as loss of 15 BCVA letters or more on two consecutive visits, or a loss at the end of the 12-month treatment period.”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

| Measure | Sham (n=89) | EM (n=89) | EOM (n=92) | ANX007 pooled (n=181) |
| --- | --- | --- | --- | --- |
| Participants with ≥15-letter loss through month 12 | “21.3% (19/89)” | “5.6% (5/89)” | “10.9% (10/92)” | “8.3% (15/181)” |
| p-value vs sham | “--” | “0.0021” | “0.055” | “0.0024” |

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

> “Over the 12-month treatment period, patients in the ANX007 monthly treatment group showed a 72% reduction in risk of >15-letter vision loss (n=89, p=0.006) and patients in the ANX007 every-other-month treatment group showed a 48% reduction in risk of >15-letter vision loss (n=92, p=0.064). Patients in the pooled treatment group showed a 59% reduction in risk of >15-letter loss (n=181, p=0.008).”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

<a id="topic-3.1.2.8.3-6"></a>

###### Confirmed BCVA ≥15-letter loss: final data under two event definitions

| Event definition and measure | Sham | Vonaprument EM | Vonaprument EOM |
| --- | --- | --- | --- |
| Through month 12 or last visit: participants with loss | “19/89” | “5/89” | “9/92” |
| Through month 12 or last visit: percentage | “21.3%” | “5.6%” | “9.8%” |
| Through month 12 or last visit: nominal p-value vs pooled sham | “---” | “0.0021” | “0.032” |
| Month 12 event confirmed at month 15: participants with loss | “15/89” | “4/89” | “8/92” |
| Month 12 event confirmed at month 15: percentage | “16.9%” | “4.5%” | “8.7%” |
| Month 12 event confirmed at month 15: nominal p-value vs pooled sham | “---” | “0.0076” | “0.0994” |

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

> “Confirmed for two consecutive visits through month 12 or at last study visit”
> “Confirmed at two consecutive visits through month 12; month 12 event confirmed at month 15”
> “Nominal p-value from a Chi-square test in ITT population”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-3.1.2.8.3-7"></a>

###### Confirmed BCVA ≥15-letter loss: analysis type and nominal significance

> “Monthly treatment with vonaprument demonstrated nominally statistically significant reduction in BCVA ≥15-letter loss (p=0.0021) compared to sham. The persistent ≥15-letter BCVA loss through month 12 hazard was reduced 72% in the monthly arm (p=0.006) and 48% in the every other month arm (p=0.064).”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

> “Results: Fewer Patients Treated with ANX007 Had Confirmed BCVA ≥15-Letter Loss Through Month 12”
> “A Prespecified Secondary Analysis”

Source: [Vakharia (2025)](https://annexonbio.com/wp-content/uploads/2025/05/Vakharia-RWC-2025-NNT.pdf)

> “Confirmed loss of 15 or more ETDRS letters as measured by BCVA”
> “was a prespecified analysis in ARCHER (loss events defined as occurring at two consecutive study visits, including month 12)”

Source: [Epshtein (2026)](https://annexonbio.com/wp-content/uploads/2026/09/Epshtein-AAOptom-Poster-.pdf)

<a id="topic-3.1.2.8.3-8"></a>

###### Time to confirmed BCVA ≥15-letter loss: Kaplan-Meier hazard ratios

> “73% Risk Reduction Vonaprument EM”
> “HR (CI) = 0.272 (0.090 to 0.819); Nominal p = 0.0119”
> “50% Risk Reduction Vonaprument EOM”
> “HR (CI) = 0.504 (0.214 to 1.189); Nominal p = 0.1098”
> “HR, hazard ratio; Nominal log-rank test (versus sham) p-values are presented”
> “Confirmed BCVA 15-LL at two consecutive visits including month 12 supported by ensuing (off-treatment) visit”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-3.1.2.8.3-9"></a>

###### Time to confirmed BCVA ≥15-letter loss: hazard ratios as presented in 2024

> “53% Risk Reduction ANX007 EOM”
> “HR (CI) = 0.504 (0.214 to 1.190); p = 0.0788”
> “73% Risk Reduction ANX007 EM”
> “HR (CI) = 0.272 (0.090 to 0.819); p = 0.0098”

Source: [Pearlman (2024)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-Pearlman-FINAL.pdf)

<a id="topic-3.1.2.8.3-10"></a>

###### Confirmed BCVA ≥10-letter and ≥20-letter loss: sensitivity analysis

| Threshold and measure | Sham | EM | EOM |
| --- | --- | --- | --- |
| ≥10-letter loss: participants with loss | “23/89” | “14/89” | “19/92” |
| ≥10-letter loss: percentage | “25.8%” | “15.7%” | “20.7%” |
| ≥10-letter loss: nominal p-value vs sham | “---” | “0.096” | “0.408” |
| ≥20-letter loss: participants with loss | “15/89” | “4/89” | “6/92” |
| ≥20-letter loss: percentage | “16.9%” | “4.5%” | “6.5%” |
| ≥20-letter loss: nominal p-value vs sham | “---” | “0.008” | “0.030” |

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

> “Confirmed for two consecutive visits through month 12 or at last visit”
> “Nominal p-value from a Chi-square test in ITT population”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-3.1.2.8.3-11"></a>

###### Additional analyses of BCVA loss presented in 2023

> “Annexon conducted additional analyses to further evaluate the effect of ANX007 treatment on BCVA and GA lesion area.”
> “Risk reduction for BCVA ≥15 letter loss was maintained in a more conservative analysis, in which events occurring at the last single-point visit were excluded.”
> “ANX007’s impact on BCVA ≥15 letter loss was consistent across patients’ baseline characteristics, including lesion size, lesion location, multifocality and others, and was not driven by any one patient subgroup.”
> “In a fellow-eye analysis, comparison of sham, monthly (EM) and every-other-month (EOM) treatment groups in the subset of patients with bilateral GA, a consistent dose-dependent trend for protection against ≥15 BCVA letter loss at the 12-month time point was shown. No protection was demonstrated in sham whereas a 74% reduction for EM and 47% reduction for EOM was demonstrated against the corresponding fellow eye groups.”

Source: [Annexon Biosciences ASRS 2023 press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-presents-archer-trial-results-asrs-2023-highlighting)

<a id="topic-3.1.2.8.3-12"></a>

###### BCVA ≥15-letter loss after treatment ended: off-treatment period

> “In a preliminary 6-month off-treatment analysis assessing vision loss after ANX007 treatment was discontinued, the rate of decline in patients with BCVA ≥15 letter loss in the treated groups accelerated to parallel the decline in the sham group.”

Source: [Annexon Biosciences ASRS 2023 press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-presents-archer-trial-results-asrs-2023-highlighting)

> “Low frequency (<0.6% per month) of single BCVA ≥15-letter losses in EM- and EOM-treated groups during 12-month treatment period”
> “While benefit was maintained after treatment cessation the rate of BCVA≥15 LL increased to parallel that of sham (>1.6% per month)”

Source: [Khurana (2025)](https://annexonbio.com/wp-content/uploads/2025/02/Khurana-MacSoc-2025-Central-Subdomains-.pdf)

<a id="topic-3.1.2.8.3-13"></a>

###### Mean change in BCVA from baseline to month 12

| Measure | ANX007 EM | ANX007 EOM | Sham |
| --- | --- | --- | --- |
| Participants analyzed | “89” | “92” | “89” |
| Mean (SE) change, letters | “-1.7(1.33)” | “-2.6(1.29)” | “-4.1(1.31)” |

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

| Measure | Sham | EM | EOM |
| --- | --- | --- | --- |
| Nominal p-value vs sham, mean change in BCVA at month 12 | “---” | “0.1904” | “0.3977” |

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

> “Nominal p-value from MMRM adjusting for baseline lesion location, lesion focality, baseline GA lesion, and the baseline GA lesion by visit interaction in ITT population”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-3.1.2.8.3-14"></a>

###### Low-luminance visual acuity: registry results

| Measure | ANX007 EM | ANX007 EOM | Sham |
| --- | --- | --- | --- |
| Change from baseline to month 12, least squares mean (SE), letters | “-1.4(1.29)” | “-2.8(1.25)” | “-4.8(1.31)” |
| Participants analyzed for ≥15-letter loss | “79” | “85” | “79” |
| Number of events with ≥15-letter LLVA loss | “6” | “8” | “16” |

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

> “LLVA ≥15-letter loss worsening from Baseline during the 12-month Treatment.”

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.8.3-15"></a>

###### Low-luminance visual acuity ≥15-letter loss: topline company counts

> “Low-luminance visual acuity: LLVA is BCVA assessed in low light conditions. ANX007 demonstrated a non-significant trend in slowing the progression of LLVA loss in the monthly, every-other-month and pooled treatment groups, which Annexon believes supports the ANX007 mechanism of action”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

| Measure | Sham (n=79) | EM (n=79) | EOM (n=85) | ANX007 pooled (n=164) |
| --- | --- | --- | --- | --- |
| Participants with ≥15-letter LLVA loss through month 12 | “20.3% (16/79)” | “10.1% (8/79)” | “11.8% (10/85)” | “11.0% (18/164)” |
| p-value vs sham | “--” | “0.076” | “0.14” | “0.051” |

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

<a id="topic-3.1.2.8.3-16"></a>

###### Low-luminance visual acuity and deficit: final data

| Measure | Sham | EM | EOM |
| --- | --- | --- | --- |
| LLVA ≥15-letter loss: participants with loss | “16/79” | “6/79” | “8/85” |
| LLVA ≥15-letter loss: percentage | “20.3%” | “7.6%” | “9.4%” |
| LLVA ≥15-letter loss: nominal p-value vs sham | “--” | “0.0216” | “0.0497” |
| LLVD ≥15-letter worsening: participants with worsening | “13/79” | “4/79” | “8/85” |
| LLVD ≥15-letter worsening: percentage | “16.5%” | “5.1%” | “9.4%” |
| LLVD ≥15-letter worsening: nominal p-value vs sham | “--” | “0.0209” | “0.1774” |
| Mean change in LLVA at month 12 | “-4.8” | “-1.4” | “-2.8” |
| Mean change in LLVA at month 12: nominal p-value vs sham | “---” | “0.0592” | “0.2664” |

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

> “Patients with at least one post-baseline LLVA measurement and two consecutive or last visit 15-letter loss events”
> “≥15-letter worsening in LLVD was defined as a change from Baseline of ≥15-letters across 2 consecutive visits, or at the last visit, through month 12”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-3.1.2.8.3-17"></a>

###### Low-luminance visual acuity ≥15-letter loss: event definition as presented in 2024

| Measure | Sham | EM | EOM |
| --- | --- | --- | --- |
| LLVA ≥15-letter loss: participants with loss | “16/79” | “6/79” | “8/85” |
| LLVA ≥15-letter loss: percentage | “20.3%” | “7.6%” | “9.4%” |
| LLVA ≥15-letter loss: nominal p-value vs sham | “--” | “0.022” | “0.050” |

Source: [Pearlman (2024)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-Pearlman-FINAL.pdf)

> “Patients with single LLVA ≥15-letter loss event and at least one post-baseline LLVA measurement”

Source: [Pearlman (2024)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-Pearlman-FINAL.pdf)

> “Statistically significant protection of vision in low light conditions, low luminance visual acuity (LLVA) at month 12, which is an important assessment of visual performance for everyday activity (LLVA ≥15-letter loss at month 12: 20.3% (sham) vs. 7.6% (ANX007 monthly); p = 0.022)”

Source: [Annexon Biosciences ARCHER II update press release (2024)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-provides-update-archer-ii-global-registrational-program)

<a id="topic-3.1.2.8.3-18"></a>

###### Low-luminance visual deficit: registry results

| Measure | ANX007 EM | ANX007 EOM | Sham |
| --- | --- | --- | --- |
| Change from baseline to month 12, least squares mean (SE), letters | “-0.4(1.55)” | “1.3(1.50)” | “0.6(1.57)” |
| Participants analyzed for ≥15-letter worsening | “79” | “85” | “79” |
| Number of events with ≥15-letter LLVD worsening | “4” | “8” | “13” |

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.8.3-19"></a>

###### Ellipsoid zone loss: photoreceptor preservation across the macula and in central subdomains

| Region | Sham participants | Vonaprument pooled participants | Reduction vs sham | Nominal p-value |
| --- | --- | --- | --- | --- |
| Pan-macula, total EZ loss | “Sham (n = 67)” | “Vonaprument pooled (n = 107)” | “27% decrease” | “0.0457” |
| Central 2.0 mm, total EZ loss | “Sham (n = 25)” | “Vonaprument pooled (n = 36)” | “48% decrease” | “0.0218” |
| Central 1.5 mm, total EZ loss | “Sham (n = 22)” | “Vonaprument pooled (n = 24)” | “59% decrease” | “0.0319” |

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

> “Nominal p-values from a linear mixed model for repeated measures model (slope) analysis”
> “Heidelberg Spectralis OCT population with baseline OCT data, excludes patients with >98% atrophy/attenuation at baseline”
> “Vonaprument treatment arms were not statistically different”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

> “Prespecified analyses included best-corrected visual acuity (BCVA) ≥15-letter loss at 2 consecutive visits and changes from baseline in EZ and RPE structure.”

Source: [Vakharia (2025)](https://annexonbio.com/wp-content/uploads/2025/05/Vakharia-RWC-2025-NNT.pdf)

<a id="topic-3.1.2.8.3-20"></a>

###### Ellipsoid zone and central retinal pigment epithelium loss: results as reported in 2024

> “ANX007 provided up to 60% protection of photoreceptors compared to sham within the central 1.5 mm of the fovea, as measured by ellipsoid zone (EZ) through 12 months (p = 0.0319*)”
> “ANX007 provided 29% protection of photoreceptors across the full retinal field as measured by EZ through 12 months (p = 0.017*)”
> “ANX007 demonstrated a trend of protection against RPE loss in the central foveal subfield, the region where RPE loss best correlates with vision loss (18% protection of RPE loss, p = 0.40*). RPE loss is a measure that lags behind photoreceptor loss.”
> “*nominal p-value”

Source: [Annexon Biosciences ARCHER II update press release (2024)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-provides-update-archer-ii-global-registrational-program)

<a id="topic-3.1.2.8.3-21"></a>

###### Subgroup analysis: BCVA ≥15-letter loss by lesion location

> “When assessing the BCVA treatment effect by lesion location, the combined analysis, stratified by foveal and non-foveal patients, demonstrated an overall statistically significant difference between ANX007 and sham”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

| Lesion location | Sham | EM | EOM | ANX007 pooled |
| --- | --- | --- | --- | --- |
| Foveal | “25.0% (11/44)” | “5.9% (3/51)” | “18.4% (9/49)” | “12.0% (12/100)” |
| Non-foveal | “17.8% (8/45)” | “5.3% (2/38)” | “2.3% (1/43)” | “3.7% (3/81)” |
| p-value vs sham | “--” | “0.0019” | “0.0439” | “0.0015” |

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

> “Nominal p-value from a Cochran Mantel-Haenszel test (General Association) in ITT population”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-3.1.2.8.3-22"></a>

###### Subgroup analysis: BCVA ≥15-letter loss by baseline low-luminance visual deficit

> “When assessing the BCVA treatment effect by retinal health, the combined analysis, stratified by healthier and less healthy retina, demonstrated an overall statistically significant difference between ANX007 and sham. This effect supports the potential use as an early treatment for GA”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

| Baseline LLVD | Sham | EM | EOM | ANX007 pooled |
| --- | --- | --- | --- | --- |
| LLVD <30 (healthier) | “16.9% (10/59)” | “0.0% (0/56)” | “6.3% (3/48)” | “2.9% (3/104)” |
| LLVD ≥30 (less healthy) | “30.8% (8/26)” | “16.1% (5/31)” | “16.3% (7/43)” | “16.2% (12/74)” |
| p-value vs sham | “--” | “0.0016” | “0.029” | “0.0009” |

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

> “Additional analyses were conducted to evaluate the effect of ANX007 on these measures in participants with relatively less advanced disease at baseline (less EZ loss and lower low luminance visual deficit [LLVD]).”

Source: [Vakharia (2025)](https://annexonbio.com/wp-content/uploads/2025/05/Vakharia-RWC-2025-NNT.pdf)

<a id="topic-3.1.2.8.3-23"></a>

###### Subgroup analysis: low-luminance visual deficit worsening by baseline BCVA

| Baseline BCVA score | Sham | EM | EOM | ANX007 pooled |
| --- | --- | --- | --- | --- |
| ≥55 (better vision) | “25.5% (13/51)” | “9.4% (5/53)” | “16.4% (9/55)” | “13.0% (14/108)” |
| <55 (impaired vision) | “17.9% (5/28)” | “7.7% (2/26)” | “3.3% (1/30)” | “5.4% (3/56)” |
| p-value vs sham | “--” | “0.0161” | “0.0597” | “0.0091” |

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

<a id="topic-3.1.2.8.3-24"></a>

###### Post hoc analysis: participants with subfoveal lesions at baseline

| Measure, subfoveal population | Sham | Vonaprument EM | Vonaprument EOM |
| --- | --- | --- | --- |
| Confirmed BCVA ≥15-letter loss: participants with loss | “10/44” | “3/51” | “7/49” |
| Confirmed BCVA ≥15-letter loss: percentage | “22.7%” | “5.9%” | “14.3%” |
| Confirmed BCVA ≥15-letter loss: nominal p-value vs sham | “---” | “.0172” | “.2930” |
| LLVA ≥15-letter loss: participants with loss | “7/41” | “2/50” | “1/48” |
| LLVA ≥15-letter loss: percentage | “17.1%” | “4.0%” | “2.1%” |
| LLVA ≥15-letter loss: nominal p-value vs sham | “---” | “.0137” | “.0377” |

Source: [Barakat (2026)](https://annexonbio.com/wp-content/uploads/2026/09/913_Friday_Barakat_-Vision-Outcomes-in-Eyes-With-Subfoveal-RPE-Lesions-in-Geographic-Atrophy-A-Post-Hoc-Analysis-of-the-Phase-2-ARCHER-Trial-FINAL-25Sept26.pdf)

> “76% Risk Reduction Vonaprument EM”
> “HR (CI) = 0.242 (0.067 to 0.881); Nominal p = .0204”
> “41% Risk Reduction Vonaprument EOM”
> “HR (CI) = 0.504 (0.225 to 1.555); Nominal p = .2784”
> “Confirmed BCVA 15-LL at two consecutive visits including month 12 supported by ensuing (off-treatment) visit; visits were monthly through Month 12 and then at Months 15 and 18”
> “Historically, GA with subfoveal involved lesions was considered too advanced to show a meaningful treatment benefit”

Source: [Barakat (2026)](https://annexonbio.com/wp-content/uploads/2026/09/913_Friday_Barakat_-Vision-Outcomes-in-Eyes-With-Subfoveal-RPE-Lesions-in-Geographic-Atrophy-A-Post-Hoc-Analysis-of-the-Phase-2-ARCHER-Trial-FINAL-25Sept26.pdf)

<a id="topic-3.1.2.8.3-25"></a>

###### Baseline characteristics associated with BCVA ≥15-letter loss

> “BCVA ≥15-letter loss did not occur in participants with baseline BCVA <44 letters”
> “BCVA ≥15-letter loss less frequent in participants with baseline BCVA >69 letters”
> “Confirmed loss of 15 or more BCVA letters was associated with:”
> “Baseline visual acuity (BCVA) above 45 letters (20/100)”
> “All lesion types – more strongly associated in those with subfoveal lesions”

Source: [Chang (2026)](https://annexonbio.com/wp-content/uploads/2026/07/MChang-ASRS-Presentation-FINAL-18Jul26.pptx.pdf)

<a id="topic-3.1.2.8.3-26"></a>

###### Number needed to treat

> “Number Needed to Treat = 1 / (21.3 – 5.6) * 100= 6.4”
> “For every 7 patients treated with ANX007 monthly, 1 additional patient would be spared clinically significant vision loss”
> “Number Needed to Treat EM To Avoid ≥10 LL = 10”
> “Number Needed to Treat EM To Avoid ≥15 LL = 7”
> “Number Needed to Treat EM To Avoid ≥20 LL = 8”

Source: [Vakharia (2025)](https://annexonbio.com/wp-content/uploads/2025/05/Vakharia-RWC-2025-NNT.pdf)

Additional sources: [Jaffe et al. (2024a)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-V1-Jaffe-FINAL-15Jul24.pdf); [Jaffe et al. (2024b)](https://annexonbio.com/wp-content/uploads/2024/09/Retina-2024-FINAL-9Sept24.pdf); [Chakravarthy et al. (2024)](https://annexonbio.com/wp-content/uploads/2024/09/Euretina-Chakravarthy-FINAL.pdf); [Khurana et al. (2024)](https://annexonbio.com/wp-content/uploads/2024/10/AAO-2024-poster-final.pdf); [Heier et al. (2024)](https://annexonbio.com/wp-content/uploads/2024/12/Heier-FloRetina-Final-Dec-2024.pdf); [Stanga et al. (2024)](https://annexonbio.com/wp-content/uploads/2024/12/Stanga-FloRetina-Final-Dec24.pdf); [Kuriyan et al. (2025)](https://annexonbio.com/wp-content/uploads/2025/05/04_11_2025_ARVO_-Kuriyan_FINAL.pdf); [Jaffe et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/Jaffe-MacSoc-2026-EZ-ELM-baseline-BCVA.pdf); [Goren Fein et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/J-Goren-Fein-RWC-Poster-FINAL-11May26.pdf); [Sharma (2026)](https://annexonbio.com/wp-content/uploads/2026/10/Sharma-Euretina.pdf); [Williams et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/10/Williams-AAO-Vision-Loss-in-Eyes-with-Subfoveal-RPE-Lesions-in-GA-Post-Hoc-Analysis-of-the-ARCHER-Trial.pdf)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Treatment-emergent adverse events through month 12, registry results

| Measure | ANX007 EM | ANX007 EOM | Sham |
| --- | --- | --- | --- |
| Participants analyzed | “89” | “92” | “89” |
| Participants with TEAEs | “65” | “68” | “68” |

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

> “Safety population included all randomized participants who received at least one dose of study drug.”

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.8.5-2"></a>

###### Deaths, serious adverse events, and other adverse events, registry results

| Measure | ANX007 EM | ANX007 EOM | Sham |
| --- | --- | --- | --- |
| All-cause mortality | “2/89 (2.25%)” | “3/92 (3.26%)” | “2/89 (2.25%)” |
| Participants with serious adverse events | “21/89 (23.60%)” | “16/92 (17.39%)” | “16/89 (17.98%)” |
| Participants with other (non-serious) adverse events | “21/89 (23.60%)” | “20/92 (21.74%)” | “23/89 (25.84%)” |

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.8.5-3"></a>

###### Ocular serious adverse events, registry results

| Serious adverse event | ANX007 EM | ANX007 EOM | Sham |
| --- | --- | --- | --- |
| Endophthalmitis | “1/89 (1.12%)” | “2/92 (2.17%)” | “0/89 (0.00%)” |
| Retinal artery occlusion | “0/89 (0.00%)” | “1/92 (1.09%)” | “0/89 (0.00%)” |
| Neovascular age-related macular degeneration | “1/89 (1.12%)” | “0/92 (0.00%)” | “0/89 (0.00%)” |
| Dry age-related macular degeneration | “1/89 (1.12%)” | “0/92 (0.00%)” | “0/89 (0.00%)” |
| Iritis | “1/89 (1.12%)” | “0/92 (0.00%)” | “0/89 (0.00%)” |
| Vitritis | “0/89 (0.00%)” | “1/92 (1.09%)” | “0/89 (0.00%)” |
| Vitreous floaters | “1/89 (1.12%)” | “0/92 (0.00%)” | “0/89 (0.00%)” |
| Visual acuity reduced | “0/89 (0.00%)” | “0/92 (0.00%)” | “1/89 (1.12%)” |

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.8.5-4"></a>

###### Non-ocular serious adverse events in two or more participants in any group, registry results

| Serious adverse event | ANX007 EM | ANX007 EOM | Sham |
| --- | --- | --- | --- |
| Atrial fibrillation | “2/89 (2.25%)” | “4/92 (4.35%)” | “0/89 (0.00%)” |
| Acute myocardial infarction | “2/89 (2.25%)” | “1/92 (1.09%)” | “0/89 (0.00%)” |
| Angina pectoris | “0/89 (0.00%)” | “2/92 (2.17%)” | “0/89 (0.00%)” |
| Pneumonia | “3/89 (3.37%)” | “2/92 (2.17%)” | “0/89 (0.00%)” |
| Urinary tract infection | “1/89 (1.12%)” | “1/92 (1.09%)” | “2/89 (2.25%)” |
| Cerebrovascular accident | “2/89 (2.25%)” | “0/92 (0.00%)” | “2/89 (2.25%)” |

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.8.5-5"></a>

###### Non-serious adverse events at a frequency of 5% or more, registry results

| Adverse event | ANX007 EM | ANX007 EOM | Sham |
| --- | --- | --- | --- |
| COVID-19 | “12/89 (13.48%)” | “10/92 (10.87%)” | “10/89 (11.24%)” |
| Urinary tract infection | “6/89 (6.74%)” | “7/92 (7.61%)” | “12/89 (13.48%)” |
| Conjunctival haemorrhage | “7/89 (7.87%)” | “6/92 (6.52%)” | “3/89 (3.37%)” |

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.8.5-6"></a>

###### Adverse events of special interest: choroidal neovascularization, endophthalmitis, vascular occlusion, vasculitis, intraocular inflammation, and ischemic optic neuropathy

| Adverse event, n (%) | Sham (N=89) | Vonaprument EM (N=89) | Vonaprument EOM (N=92) |
| --- | --- | --- | --- |
| Choroidal neovascularization | “3 (3.4%)” | “4 (4.5%)” | “4 (4.3%)” |
| Endophthalmitis | “0” | “1 (1.1%)” | “2 (2.2%)” |
| Retinal vascular occlusion | “0” | “0” | “1^ (1.1%)” |
| Retinal vasculitis | “0” | “0” | “0” |
| Intraocular inflammation | “0” | “2 (2.2%)” | “1 (1.1%)” |
| Ischemic optic neuropathy | “0” | “0” | “0” |

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

> “Iritis – 1”
> “Resolved with topical steroids in 2 days”
> “Vitritis – 1”
> “Resolved with topical steroids in 9 days”
> “Vitreous Debris – 1”
> “KP on endothelium, prior treatment with topical steroids”
> “Isolated cilioretinal artery occlusion; no vasculitis confirmed by DSMC and reading center”
> “Not AESI, included because of current interest”
> “CNV rate generally similar across sham and treatment arms”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-3.1.2.8.5-7"></a>

###### Endophthalmitis, intraocular inflammation, and retinal artery occlusion: topline description

> “Among the patients treated with ANX007, three serious adverse events (SAEs) of endophthalmitis were observed, which were determined to be related to intravitreal injection procedure and not related to treatment. There were three SAEs of intraocular inflammation, suspected of being treatment-related, which were not associated with retinal vasculitis. One SAE of retinal artery occlusion was reported, suspected of being treatment-related, which was also not associated with retinal vasculitis.”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

<a id="topic-3.1.2.8.5-8"></a>

###### Choroidal neovascularization and retinal vasculitis

> “There was a limited incidence of choroidal neovascularization (CNV) conversion across all three groups, with 3.4% in the sham group vs. 4.5% and 4.3% in the ANX007 monthly and every-other-month groups, respectively.”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

> “Vonaprument treatment was generally well-tolerated, with no increase in CNV rates between the treated and sham arms and no events of retinal vasculitis reported.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary: missed primary endpoint, reliance on secondary and post hoc analyses, and unpublished results

- Primary endpoint: ARCHER did not meet its primary endpoint, the rate of change (slope) in geographic atrophy lesion area by fundus autofluorescence from baseline to month 12. In the registry analysis, which included non-subfoveal participants only, the slope was 2.0837 mm²/year in 81 participants receiving pooled vonaprument and 1.9019 mm²/year in 45 participants receiving sham. Annexon reported reductions in lesion growth of 6.2% with monthly dosing (p=0.526), 1.3% with every-other-month dosing (p=0.896), and 3.7% for the pooled groups (p=0.673).
- Efficacy claims rest on secondary, exploratory, and post hoc analyses: BCVA ≥15-letter loss is a secondary outcome on the registry record and is labeled “A Prespecified Secondary Analysis” in a 2025 presentation. The Form 10-K describes the monthly-arm result as “nominally statistically significant”, and the company presentations of 2024 to 2026 label their p-values as nominal. The analyses of eyes with subfoveal lesions are labeled post hoc, and the company describes the analyses of less advanced disease, BCVA ≥10-letter and ≥20-letter loss, fellow eyes, and the off-treatment period as additional or sensitivity analyses. Mean change in BCVA at month 12 was -1.7 letters with monthly dosing, -2.6 with every-other-month dosing, and -4.1 with sham, with nominal p-values of 0.1904 and 0.3977.
- Discrepant event counts: the registry reports 4, 8, and 15 events of confirmed BCVA ≥15-letter loss (monthly, every other month, sham), defined as loss at 2 consecutive visits. The topline release reported 5 of 89 (5.6%), 10 of 92 (10.9%), and 19 of 89 (21.3%) participants, counting loss on two consecutive visits or a loss at the end of the 12-month treatment period. The 2026 presentation reports 5 of 89, 9 of 92, and 19 of 89 under “two consecutive visits through month 12 or at last study visit” (nominal p=0.0021 and 0.032), and 4 of 89, 8 of 92, and 15 of 89 when the month 12 event is confirmed at month 15 (nominal p=0.0076 and 0.0994). Under the definition that reproduces the registry counts, the every-other-month result is not nominally significant.
- Changing analyses between presentations: the topline release reported LLVA ≥15-letter loss in 8 of 79 participants (10.1%) with monthly dosing and 16 of 79 (20.3%) with sham (p=0.076), described as a “non-significant trend”. Later presentations report 6 of 79 (7.6%) with p=0.022 or 0.0216; the 2024 presentation attributes these counts to a “single LLVA ≥15-letter loss event”, and the 2026 presentation attributes the same counts to “two consecutive or last visit 15-letter loss events”. The nominal p-value for the monthly hazard ratio of 0.272 is 0.0098 in the 2024 presentation and 0.0119 in the 2026 presentation, and for the every-other-month hazard ratio of 0.504 it is 0.0788 and 0.1098. The ellipsoid zone result across the full retinal field was 29% (p=0.017) in the 2024 release and a 27% decrease (p=0.0457) in 107 vonaprument and 67 sham participants in the 2026 presentation; the central 1.5 mm and 2.0 mm subdomain analyses include 46 and 61 participants.
- No peer-reviewed publication: no journal article reporting ARCHER results was identified. The registry record states a restrictive agreement under which investigator-initiated publications wait until all protocol-defined results are published in a manuscript. The available results come from the registry, press releases, the Form 10-K, investor presentations, and congress presentations that state Annexon sponsorship, with authors who are employees and equity owners of Annexon Biosciences.
- Applicability: the treatment period was 12 months, followed by 6 months off treatment, during which the rate of BCVA ≥15-letter loss in the treated groups increased to parallel sham. Ninety-six percent of participants were enrolled in the United States. ARCHER II did not enroll individuals with baseline BCVA <45 letters, because ARCHER showed a very low incidence of BCVA 15-letter loss in that group, so the phase 3 population differs from the phase 2 population. The phase 3 trial tests monthly dosing only.

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results); [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic); [Annexon Biosciences ASRS 2023 press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-presents-archer-trial-results-asrs-2023-highlighting); [Annexon Biosciences ARCHER II update press release (2024)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-provides-update-archer-ii-global-registrational-program); [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm); [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c); [Pearlman (2024)](https://annexonbio.com/wp-content/uploads/2024/07/ASRS-Pearlman-FINAL.pdf); [Khurana (2025)](https://annexonbio.com/wp-content/uploads/2025/02/Khurana-MacSoc-2025-Central-Subdomains-.pdf); [Vakharia (2025)](https://annexonbio.com/wp-content/uploads/2025/05/Vakharia-RWC-2025-NNT.pdf); [Barakat (2026)](https://annexonbio.com/wp-content/uploads/2026/09/913_Friday_Barakat_-Vision-Outcomes-in-Eyes-With-Subfoveal-RPE-Lesions-in-Geographic-Atrophy-A-Post-Hoc-Analysis-of-the-Phase-2-ARCHER-Trial-FINAL-25Sept26.pdf); [Goren Fein et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/J-Goren-Fein-RWC-Poster-FINAL-11May26.pdf); [Jaffe et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/Jaffe-MacSoc-2026-EZ-ELM-baseline-BCVA.pdf)

<a id="topic-3.1.2.9-2"></a>

###### Primary endpoint not met

> “Reduction in rate of geographic atrophy lesion growth did not reach statistical significance”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

> “While the primary endpoint of mean rate of change (slope) in GA lesion area compared to sham at 12 months did not reach statistical significance, greater impact on retinal pigment epithelium loss was observed in the second six months of treatment versus the first.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-3.1.2.9-3"></a>

###### Restrictive publication agreement on the registry record

> “Written approval from the Sponsor is required before disclosing any information relative to this clinical study, and no publications initiated by Investigators may be published until all protocol-defined results are published in a manuscript.”

Source: [ClinicalTrials.gov NCT04656561 results](https://clinicaltrials.gov/study/NCT04656561?tab=results)

<a id="topic-3.1.2.9-4"></a>

###### Post hoc analyses with nominal p-values

> “Post-hoc analysis; all p-values are nominal”

Source: [Jaffe et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/Jaffe-MacSoc-2026-EZ-ELM-baseline-BCVA.pdf)

<a id="topic-3.1.2.9-5"></a>

###### Sponsor employment and sponsorship of congress presentations

> “SB, LT, RD, XT, WLC: Employment with and equity ownership in Annexon Biosciences, Inc.”
> “These studies sponsored by Annexon Biosciences (Brisbane, California, USA)”

Source: [Goren Fein et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/J-Goren-Fein-RWC-Poster-FINAL-11May26.pdf)

> “Vladislav Volman, Scott Borland, Lori Taylor, Kimberly Reed, W. Lloyd Clark, Margot Goodkin, Erik Pulkstenis, Jamie Dananberg, Ted Yednock, Alessia Tassoni: Owners and Employees of Annexon Biosciences”

Source: [Jaffe et al. (2026)](https://annexonbio.com/wp-content/uploads/2026/05/Jaffe-MacSoc-2026-EZ-ELM-baseline-BCVA.pdf)

<a id="topic-3.1.2.9-6"></a>

###### Phase 3 population restricted after the phase 2 results

> “Individuals with baseline BCVA <45 letters not enrolled in ARCHER II due to very low incidence of BCVA 15-letter loss in ARCHER”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-3.1.2.9-7"></a>

###### Enrollment concentrated in the United States

> “Ninety-six percent of patients enrolled were from the United States.”

Source: [Annexon Biosciences ARCHER topline press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic)

<a id="heading-3.1.3"></a>

#### 3.1.3 AiiM OLE

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Registered purpose of the extension study

> “The primary purpose of the study is to assess the long term safety of intravitreal (IVT) injections of vonaprument.”

Source: [ClinicalTrials.gov NCT07807969](https://clinicaltrials.gov/study/NCT07807969)

<a id="topic-3.1.3.1-2"></a>

###### Company statement of the extension study objective

> “The OLE study is designed to evaluate the long-term safety and benefit of vonaprument in patients with GA.”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

<a id="topic-3.1.3.1-3"></a>

###### Extension data intended for the label

> “Upon completion of Month 24, all patients will have the option to receive monthly vonaprument treatment in the open-label extension (OLE) study, designed to evaluate the longer-term profile of vonaprument for inclusion in the label.”

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Registry dates for the extension study

| Milestone | Registry record |
| --- | --- |
| First posted | “2026-09-08” |
| Study start (estimated) | “2026-09-30” |
| Primary completion (estimated) | “2029-07-31” |
| Study completion (estimated) | “2029-07-31” |

Source: [ClinicalTrials.gov NCT07807969](https://clinicaltrials.gov/study/NCT07807969)

<a id="topic-3.1.3.2-2"></a>

###### Registered extension study sites

> “Retina Group of Florida”
> “Retina Vitreous Associates of Florida”
> “Cumberland Valley Retina Consultants”
> “Mid Atlantic Retina Specialists”
> “Retina Research Institute at New England Retina Consultants”
> “Asheville Eye Associates - Retina Division”
> “Verum Research, LLC”

Source: [ClinicalTrials.gov NCT07807969](https://clinicaltrials.gov/study/NCT07807969)

<a id="topic-3.1.3.2-3"></a>

###### Extension study identifiers

| Item | Registry record |
| --- | --- |
| Sponsor protocol number | “ANX007-GA-03” |
| EU CT number | “2026-527023-96-00” |
| Acronym | “AiiM OLE” |

Source: [ClinicalTrials.gov NCT07807969](https://clinicaltrials.gov/study/NCT07807969)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Registered design of the extension study

> “A Multicenter, Open-Label Extension Study of the Long-Term Safety of Vonaprument (ANX007) Administered by Intravitreal Injection in Participants With Dry Age-Related Macular Degeneration With Geographic Atrophy”

Source: [ClinicalTrials.gov NCT07807969](https://clinicaltrials.gov/study/NCT07807969)

<a id="topic-3.1.3.3-2"></a>

###### Entry into the extension after the ARCHER II Month 24 visit

> “Upon completion of Month 24, all patients have the option to receive monthly vonaprument treatment in the OLE study.”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

<a id="topic-3.1.3.3-3"></a>

###### Regulatory acceptance of the extension study data

> “There can be no assurance that the FDA and comparable regulatory authorities will accept the data from our Phase 3 program, including the amended dual primary endpoint design or the OLE study, or that such data will be determined sufficient to support approval.”

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Registered inclusion and exclusion criteria for the extension study

> “Participants with a diagnosis of dry AMD with GA who completed the Phase 3 ARCHER II study (NCT06510816) and who had not permanently ceased receiving the assigned masked treatment (IVT or Sham administration) at/before the ARCHER II Month 24 Visit.”
> “Any event or condition arising during the ARCHER II study that would put the participant in danger or lead to undue harm by participating in this OLE study.”

Source: [ClinicalTrials.gov NCT07807969](https://clinicaltrials.gov/study/NCT07807969)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Registered extension study arm and intervention

| Item | Registry record |
| --- | --- |
| Arm | “Participants will receive vonaprument IVT injections every month for 24 months.” |
| Intervention | “Form: solution for injection; Route of Administration: IVT injection” |

Source: [ClinicalTrials.gov NCT07807969](https://clinicaltrials.gov/study/NCT07807969)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Registered primary outcome of the extension study

| Outcome | Time frame |
| --- | --- |
| “Number of Participants with Treatment Emergent Adverse Events” | “Through Month 24” |

Source: [ClinicalTrials.gov NCT07807969](https://clinicaltrials.gov/study/NCT07807969)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Estimated enrollment in the extension study

| Item | Registry record |
| --- | --- |
| Estimated enrollment | “605” |

Source: [ClinicalTrials.gov NCT07807969](https://clinicaltrials.gov/study/NCT07807969)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

No evidence found.

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary: extension study not yet started

The AiiM OLE study (NCT07807969) was registered as not yet recruiting, with an estimated start date of September 30, 2026 and an estimated primary completion date of July 31, 2029, so no participant data exist. It is a single-group, open-label design with no masking and no comparator arm, and its registered primary outcome is the number of participants with treatment-emergent adverse events through Month 24; any efficacy observations it yields will lack a concurrent control. Enrollment is limited to participants who completed ARCHER II and had not permanently ceased their assigned masked treatment at or before the Month 24 visit, so the extension population is a selected subset of the ARCHER II population. The company states that the extension is designed to evaluate the “longer-term profile of vonaprument for inclusion in the label”, and its 10-Q states that there is no assurance that regulators will accept data from the OLE study.

Source: [ClinicalTrials.gov NCT07807969](https://clinicaltrials.gov/study/NCT07807969); [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

<a id="heading-3.1.4"></a>

#### 3.1.4 ANX007-GLA-02

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Registered primary, secondary, and exploratory objectives of the phase 1b study

> “The primary objective is to evaluate the safety and tolerability of repeat IVT injections of ANX007 in participants with primary open-angle glaucoma. Secondary objectives are to evaluate the anterior chamber fluid pharmacokinetics (PK) of ANX007, PD effect of ANX007 on anterior chamber fluid C1q activity, and immunogenicity. An exploratory objective will evaluate ocular PD effect of ANX007.”

Source: [ClinicalTrials.gov NCT04188015](https://clinicaltrials.gov/study/NCT04188015)

<a id="topic-3.1.4.1-2"></a>

###### Published objective of the repeat-dose study

> “The phase Ib study was a double-masked, randomized, sham-controlled trial evaluating 2 dose levels of ANX007 (2.5 mg and 5 mg) to determine the safety and tolerability (primary objectives) of 2 repeat monthly IVT injections (NCT04188015).”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Registry dates for the phase 1b study

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2018-07-25” |
| Primary completion (actual) | “2019-06-03” |
| Study completion (actual) | “2019-06-03” |

Source: [ClinicalTrials.gov NCT04188015](https://clinicaltrials.gov/study/NCT04188015)

<a id="topic-3.1.4.2-2"></a>

###### Phase 1b study sites

> “The phase Ib study was conducted at 2 sites in the United States.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

> “Eye Research Foundation”
> “Stanford Health Care”

Source: [ClinicalTrials.gov NCT04188015](https://clinicaltrials.gov/study/NCT04188015)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Registered design of the phase 1b study

> “A Phase 1b, Randomized, Double-masked, Sham-controlled Study of ANX007 Administered as Intravitreal Injections to Assess Safety and Tolerability in Participants With Primary Open-angle Glaucoma”
> “This is a phase 1b, double-masked, sham-controlled study evaluating 2 dose levels of ANX007 administered as 2 IVT injections separated by 4 weeks.”

Source: [ClinicalTrials.gov NCT04188015](https://clinicaltrials.gov/study/NCT04188015)

<a id="topic-3.1.4.3-2"></a>

###### Published design of the two glaucoma studies

> “An open-label, single-dose-escalation phase Ia study followed by a double-masked, randomized, sham-controlled, repeat-injection phase Ib study.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Published inclusion criteria for the phase 1b study

> “In the phase Ib study, eligible patients were aged ≥ 18 years, of either sex, with primary open-angle glaucoma with a mean deviation of −3 to −24 decibels (dB) on a reliable visual field test using the Humphrey field analyzer in the study eye as determined at screening, and an IOP < 21 mm Hg at screening and day 1, with no change to the IOP treatment regimen anticipated throughout study participation.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.4.4-2"></a>

###### Registered exclusion criteria for the phase 1b study

> “Extensive glaucomatous visual-field damage with a mean deviation worse than -18 dB on Humphrey visual field testing.”
> “Any current or prior ocular pathology, other than glaucoma, which could interfere with the conduct of the study including, but not limited to, retinal or optic nerve disease and media opacity in the study eye.”
> “Concurrent use of glucocorticoid medications administered by any ocular or systemic route.”
> “Previous treatment with another humanized monoclonal antibody, Fab or Fab'2.”
> “History of any autoimmune or neurologic disease.”

Source: [ClinicalTrials.gov NCT04188015](https://clinicaltrials.gov/study/NCT04188015)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Repeat-dose randomization and injection volumes

> “In the repeat-dose phase Ib study, patients were randomized to receive 2 injections 4 weeks apart (day 1 and day 29) of sham (no ocular penetration) or 2.5 mg ANX007 or 5.0 mg ANX007. Doses were administered at volumes of 20 μL (1 mg dose), 50 μL (2.5 mg dose), and 100 μL (5 mg dose), respectively.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.4.5-2"></a>

###### Sham procedure

> “For the sham injection, the preparation was identical to injection with ANX007. The sham injection was performed by applying pressure to the eye at the location of a typical IVT injection using the blunt end of an empty syringe without a needle.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.4.5-3"></a>

###### Registered phase 1b arms

| Arm | Registry description |
| --- | --- |
| 2.5 mg ANX007 | “A single dose of 2.5mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.” |
| 5.0 mg ANX007 | “A single dose of 5.0mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.” |
| Sham procedure | “1 in every 3 subjects will have a sham procedure performed instead of receiving ANX007.” |

Source: [ClinicalTrials.gov NCT04188015](https://clinicaltrials.gov/study/NCT04188015)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Registered primary and secondary outcomes of the phase 1b study

| Outcome | Time frame |
| --- | --- |
| “To evaluate the safety and tolerability of ANX007 in participants with primary open-angle glaucoma as measured by occurrence of treatment-emergent adverse events.” | “Day 85” |
| “Evaluate PK parameters of ANX007 in aqueous humor after repeat intravitreal injections” | “Day 29” |
| “Evaluate PD parameters of ANX007 in aqueous humor after repeat intravitreal injections” | “Day 29” |
| “Evaluate PD parameters of ANX007 in serum after repeat intravitreal injections” | “Day 29” |
| “Immunogenicity of ANX007 as measured by serum anti-drug antibodies (ADA) after repeat intravitreal injections of ANX007” | “Day 84” |

Source: [ClinicalTrials.gov NCT04188015](https://clinicaltrials.gov/study/NCT04188015)

<a id="topic-3.1.4.6.1-2"></a>

###### Safety assessments and follow-up in the phase 1b study

> “In the repeat-dose phase Ib study, patients were followed for a total of 12 weeks for safety, tolerability, PK (unbound ANX007 concentration in serum and aqueous humor)”
> “The safety assessments included AEs, vital signs, physical examination, urinalysis, complete blood count, serum chemistries, best corrected visual acuity assessment, slit-lamp examination, IOP measurement, and dilated fundoscopy.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.4.6.1-3"></a>

###### Aqueous humor C1q as a measure of retinal target engagement

> “Inhibition of C1q in the aqueous humor is anticipated to represent inhibition of C1q in relevant sites of neurodegenerative ophthalmic disease within the retina.”
> “In these animal studies, complete C1q target engagement in the aqueous humor reflected complete target engagement in the vitreous and retinal tissue, with measurable unbound drug at these sites in the back of the eye (Annexon, data on file).”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

> “These patients had aqueous humor taps so that ocular fluid could be analyzed for levels of vonaprument and free C1q”
> “immediately prior to first dose (day 1) and prior to second dose (day 29).”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-3.1.4.6.1-4"></a>

###### Aqueous humor sampling and assays

> “Aqueous humor was collected only in the phase Ib study per investigator standard of care into a tube provided for the study.”
> “Plate-captured C1q was detected using a monoclonal mouse anti-C1q antibody-alkaline phosphatase conjugate that binds to the same site as ANX007, thus enabling measurement of free C1q levels.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Planned and enrolled participants in the phase 1b study

> “Approximately 15-29 subjects will be enrolled. An interim analysis of the initial set of 15 participants may be conducted. Based on this analysis, an additional 10-14 participants may be enrolled at a 1:1 ratio to receive one of the two dose levels.”

Source: [ClinicalTrials.gov NCT04188015](https://clinicaltrials.gov/study/NCT04188015)

> “Seventeen patients (mean Humphrey visual field deviation between −3 and −24 dB) were enrolled in phase Ib and randomized to 2 monthly doses of ANX007 (sham, n = 6; 2.5 mg ANX007, n = 6; or 5 mg ANX007, n = 5).”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Descriptive analysis without hypothesis testing

> “No formal comparisons or hypothesis testing were planned for comparisons between dosing levels evaluated in either study, and data are presented descriptively throughout. Descriptive statistics for categorical variables included counts and percentages. Descriptive statistics for continuous variables included means, medians, standard deviation (SD), and minimum and maximum values.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

###### Treated participants and early terminations in the phase 1b study

> “In the phase Ib study, 18 patients were included in the study and 17 received study treatment. One patient was randomized to receive ANX007 2.5 mg but terminated participation in the study and did not receive any study treatment due to elevated IOP on day 1.”
> “One patient with pseudo-exfoliative glaucoma in the sham group terminated the study early after receiving the day 1 injection due to protocol violation (pseudo-exfoliation glaucoma was not recognized as included in primary open angle glaucoma inclusion criteria).”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

###### Demographics of the phase 1b study by arm

| Characteristic | Sham (n = 6) | ANX007 2.5 mg (n = 6) | ANX007 5.0 mg (n = 5) | Overall (n = 17) |
| --- | --- | --- | --- | --- |
| Age, mean (SD), yr | “70.2 (22.8)” | “60.3 (16.2)” | “74.0 (8.0)” | “67.8 (17.2)” |
| Age, median (min, max), yr | “79.5 (24, 82)” | “58.5 (35, 78)” | “74.0 (65, 86)” | “75.0 (24, 86)” |
| Male, n (%) | “4 (66.7)” | “2 (33.3)” | “2 (40.0)” | “8 (47.1)” |
| Female, n (%) | “2 (33.3)” | “4 (66.7)” | “3 (60.0)” | “9 (52.9)” |
| Black/African American, n (%) | “0” | “1 (16.7)” | “0” | “1 (5.9)” |
| Asian, n (%) | “1 (16.7)” | “1 (16.7)” | “1 (20.0)” | “3 (17.6)” |
| White, n (%) | “5 (83.3)” | “4 (66.7)” | “4 (80.0)” | “13 (76.5)” |
| Weight, mean (SD), kg | “74.8 (20.3)” | “79.7 (10.1)” | “88.4 (15.0)” | “80.5 (15.8)” |

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.4.8.2-2"></a>

###### Overall phase 1b study population

> “The majority of patients were female (n = 9, 52.9%) and White (n = 13, 76.5%), with a mean age (SD) of 67.8 (17.2) years (Table 1).”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Aqueous humor C1q target engagement at day 29

> “Correspondingly, mean (SD) and median (min, max) unbound C1q at day 1 (preinjection) was 100.1 (99.9) and 51.6 (16, 254) ng/ml in sham, 110.0 (109.5) and 65.7 (23, 293) in the ANX007 2.5 mg dose group, and 110.0 (83.1) and 86.8 (14, 222) in the ANX007 5.0 mg dose groups. Unbound C1q was reduced to undetectable levels at day 29 (< 0.6 ng/ml) in aqueous humor at both dose levels in all subjects (Fig 4).”
> “Full engagement of C1q in the aqueous humor at day 29 in all treated subjects supports monthly or less-frequent dosing of ANX007 in future clinical studies.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

> “achieved complete suppression of C1q at 2.5 mg and 5 mg.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

> “Patient aqueous humor PK/PD supports 5mg at least monthly intravitreal injection”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-3.1.4.8.3-2"></a>

###### Aqueous humor drug concentrations at day 29

> “Mean (SD) and median (min, max) ANX007 levels in aqueous humor on day 29 were 911 ng/ml (846) and 631 (225, 2539) ng/ml in the ANX007 2.5 mg dose group and 5345 ng/ml (6351) and 3111 (413, 12 512) ng/ml in the ANX007 5.0 mg dose group (Fig 3).”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.4.8.3-3"></a>

###### Systemic pharmacokinetics and pharmacodynamics after repeat dosing

> “The PK and PD analyses conducted in the phase 1b study demonstrated detectable levels of ANX007 and corresponding complete reduction of free C1q in the aqueous humor following IVT injection with ANX007 at both the 2.5 and 5.0 mg dose levels through 29 days after the first injection. Importantly, no PK or PD changes were observed in the systemic circulation.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Adverse events in the phase 1b study by arm

| n (%) | Sham (n = 6) | ANX007 2.5 mg (n = 7) | ANX007 5 mg (n = 5) | Overall (n = 18) |
| --- | --- | --- | --- | --- |
| Any TEAE | “2 (33.3)” | “2 (33.3)” | “2 (40.0)” | “6 (33.3)” |
| Ocular disorders | “2 (33.3)” | “2 (33.3)” | “2 (40.0)” | “6 (33.3)” |
| Infection | “0” | “1 (16.7)” | “0” | “1 (5.5)” |
| Injury | “0” | “1 (16.7)” | “0” | “1 (5.5)” |
| Treatment-related TEAE | “2 (33.3)” | “1 (16.7)” | “2 (40.0)” | “5 (27.8)” |
| Conjunctival hemorrhage | “0” | “0” | “1 (20.0)” | “1 (5.5)” |
| Conjunctival hyperemia | “0” | “1 (16.7)” | “0” | “1 (5.5)” |
| Eye irritation | “1 (16.7)” | “0” | “1 (20.0)” | “2 (11.1)” |
| Foreign body sensation in eyes | “1 (16.7)” | “0” | “0” | “1 (5.5)” |
| Ocular hyperemia | “1 (16.7)” | “0” | “0” | “1 (5.5)” |
| Vision blurred | “1 (16.7)” | “0” | “0” | “1 (5.5)” |

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.4.8.5-2"></a>

###### Serious, severe, and treatment-emergent adverse events after repeat dosing

> “No serious AEs, severe TEAEs, or fatal AEs were reported in any group at any time during the study. A total of 6 TEAEs were reported, 2 events in each dose level. Treatment-emergent AEs included conjunctival hemorrhage, conjunctival hyperemia, eye irritation/pain, foreign body sensation in the eyes, ocular hyperemia, blurry vision, and 1 systemic TEAE of bronchitis, which was not assessed to be related to ANX007 (Table 2). All TEAEs were mild in severity and none resulted in study discontinuation. All resolved by study closure. No drug-specific safety signals were observed, and there were no clinically significant laboratory results during study.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.4.8.5-3"></a>

###### Intraocular pressure after repeat dosing

> “Intraocular pressure returned to normal levels (≤ 21 mm Hg) within 45 minutes for all patients and within 30 minutes for 16/17 (94.1%) patients. Mean IOP measurements were within normal limits (≤ 21 mm Hg) at all time points.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.4.8.5-4"></a>

###### Best corrected visual acuity through day 84

> “Between baseline and day 84, the mean (SD) logarithm of the minimum angle of resolution results for the study eye decreased (representing improved visual acuity) in the Sham (−0.073 ± 0.0485) and ANX007 2.5 mg (−0.032 ± 0.1001) groups but increased (representing worsened visual acuity) in the ANX007 5.0 mg group (0.024 ± 0.0485) (Fig 2).”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.4.8.5-5"></a>

###### Anti-drug antibodies after repeat dosing

> “Low levels of ADA positivity were detected in 7 patients (1 patient in the sham group, 3 patients in the ANX007 2.5 mg group, and 3 patients in the ANX007 5 mg group). The signal in the ADA assay was marginally above the cut points. Of these, 5 patients (1 patient in the sham group, 1 patient in the ANX007 2.5 mg group, and 3 patients in the ANX007 5 mg group) were ADA-positive at all time points, including the predosing period, without any dose-related changes.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary: glaucoma population, small sample, and short follow-up

ANX007-GLA-02 enrolled participants with primary open-angle glaucoma, a population that differs from the geographic atrophy population of the phase 2 and phase 3 trials. Seventeen participants received study treatment (sham, 6; 2.5 mg, 6; 5 mg, 5), follow-up lasted 12 weeks with 2 injections given 4 weeks apart, and no formal comparisons or hypothesis testing were planned, so the results are descriptive. The safety table lists 7 participants in the 2.5-mg column and 18 overall, while the text reports 6 participants treated with 2.5 mg and 17 treated overall. Target engagement was measured in aqueous humor, which the authors state is “anticipated to represent” inhibition of C1q in the retina, supported by nonhuman primate data on file. The 5-mg dose was given in 100 μL in this study, while the ongoing phase 3 ARCHER II trial administers 5 mg in a 25-microliter dose. Low-level anti-drug antibody positivity was detected in 7 participants, including 1 in the sham group, which the authors attribute to likely false positives in the assay.

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/); [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-3.1.4.9-2"></a>

###### Author-stated limitations of the phase 1b study

> “When considering the results of these data in a broader context, it should be noted that the relatively small sample size and descriptive nature of the analyses preclude formal clinical endpoint comparisons between the sham and treatment groups in the phase Ib study and also between the dose levels evaluated. Additional data from larger cohorts will add to our understanding of safety and efficacy at different dosing levels.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.5"></a>

#### 3.1.5 ANX007-GLA-01

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Registered primary, secondary, and exploratory objectives of the phase 1a study

> “The primary objective is to evaluate the safety and tolerability of a single intravitreal (IVT) injection of ANX007 in participants with primary open-angle glaucoma. Secondary objectives are to evaluate the serum pharmacokinetics (PK) and immunogenicity. An exploratory objective will evaluate the pharmacodynamic (PD) effect of ANX007 on serum C1q activity.”

Source: [ClinicalTrials.gov NCT03488550](https://clinicaltrials.gov/study/NCT03488550)

<a id="topic-3.1.5.1-2"></a>

###### Published objective of the first-in-human study

> “The phase Ia study was a first-in-human, open-label (no masking), dose-escalation safety study that evaluated 3 dose levels of ANX007 administered as single IVT injections (NCT03488550).”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.5.1-3"></a>

###### Company statement of the objectives of the glaucoma studies

> “We completed single-ascending dose (n=9) and sham-controlled multiple dose (n=17) studies of intravitreal vonaprument in patients with glaucoma to evaluate safety, tolerability, pharmacokinetics and target engagement.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### Registry dates for the phase 1a study

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2018-03-23” |
| Primary completion (actual) | “2018-08-03” |
| Study completion (actual) | “2018-08-03” |

Source: [ClinicalTrials.gov NCT03488550](https://clinicaltrials.gov/study/NCT03488550)

<a id="topic-3.1.5.2-2"></a>

###### Phase 1a study site

> “The phase Ia study was conducted at a single site in the United States.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

> “Eye Research Foundation”

Source: [ClinicalTrials.gov NCT03488550](https://clinicaltrials.gov/study/NCT03488550)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Registered design of the phase 1a study

> “A Phase 1, Open-label, Single-dose, Dose-escalation, Safety, Tolerability, and PK Study of Intravitreal ANX007 in Participants With Primary Open-angle Glaucoma”
> “This is a phase 1, open-label, dose-escalation, safety study evaluating up to 3 dose levels of ANX007 administered as single IVT injections.”

Source: [ClinicalTrials.gov NCT03488550](https://clinicaltrials.gov/study/NCT03488550)

<a id="topic-3.1.5.3-2"></a>

###### Dose escalation and dose-limiting toxicity criteria

> “In the dose-escalation phase Ia study, patients were enrolled into the lowest open cohort in an open-label manner and received a single dose of ANX007 at 1 of 3 dose levels (1 mg, 2.5 mg, or 5.0 mg), with cohort dose escalation in the absence of any dose-limiting toxicity. Dose-limiting toxicity criteria were defined as any of the following adverse events (AEs) occurring within 2 weeks after an IVT injection and considered to be related to ANX007: intraocular inflammation of at least grade 2, using the Standardization of Uveitis Nomenclature criteria, that was unresponsive to topical corticosteroid therapy; increase in IOP > 30 mm Hg that was unresponsive to topical or oral IOP-lowering medications; or loss of best corrected visual acuity of > 3 Snellen lines from baseline, excluding a transient loss immediately after IVT injection.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Published inclusion criteria for the phase 1a study

> “In the phase Ia study, eligible patients were aged ≥ 18 years, of either sex, with primary open-angle glaucoma on stable IOP-lowering medications, with a mean deviation of −3 to −18 dB on a reliable visual field test using the Humphrey field analyzer in the study eye, and an IOP < 21 mm Hg for ≥ 4 weeks before dosing, with no change to the IOP treatment regimen anticipated throughout study participation.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.5.4-2"></a>

###### Key exclusion criteria for both glaucoma studies

> “For both studies, key exclusion criteria included intraocular inflammatory or infectious eye disease; uncomplicated cataract surgery < 3 months before injection; trabeculectomy, iridotomy, vitrectomy, or other incisional ocular procedures in the study eye that could affect drug distribution and excretion; and history of autoimmune or neurologic disease.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.5.4-3"></a>

###### Registered exclusion criteria for the phase 1a study

> “BCVA worse than 20/80 in either eye”
> “Extensive glaucomatous visual-field damage”
> “History of uncomplicated cataract surgery less than 6 mos prior”
> “Previous tx with another humanized monoclonal antibody”

Source: [ClinicalTrials.gov NCT03488550](https://clinicaltrials.gov/study/NCT03488550)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Single-dose cohorts

> “Nine patients with primary open-angle glaucoma (mean Humphrey visual field deviation between −3 and −18 decibels [dB]) were enrolled in phase Ia and received single doses of ANX007 (1.0 mg, n = 3; 2.5 mg, n = 3; or 5.0 mg, n = 3).”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.5.5-2"></a>

###### Intravitreal injection procedure

> “Intravitreal injection was performed under sterile conditions. Topical proparacaine was used for anesthesia. Lid margins were cleaned with Povidone-iodine 10% and povidone-iodine 5% was applied to the conjunctival surface, including the injection site. For ANX007 injection, the needle was inserted perpendicular to the sclera, 3.5 to 4 mm posterior to the limbus, between the vertical and horizontal rectus muscles.”
> “Intraocular pressure was checked postinjection. Topical antibiotics were not used postinjection.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Adverse Events as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

###### Registered outcomes of the phase 1a study

| Outcome | Time frame |
| --- | --- |
| “Safety and tolerability as measured by the occurrence of adverse events” | “Day 56” |
| “Serum plasma concentration of ANX007 after a single IVT injection.” | “Day 15” |
| “Immunogenicity of ANX007 after a single IVT injection.” | “Day 56” |
| “Effect of a single IVT injection of ANX007 on serum C1q” | “Day 15” |

Source: [ClinicalTrials.gov NCT03488550](https://clinicaltrials.gov/study/NCT03488550)

<a id="topic-3.1.5.6.1-2"></a>

###### Follow-up and sampling in the phase 1a study

> “In the dose-escalation phase Ia study, patients were followed for a total of 8 weeks for safety, tolerability, PK (unbound ANX007 serum concentration)”
> “In the single-dose study, samples for PK and PD analyses were obtained preinjection and 3 hours postinjection on day 1, and on days 2, 4, 8, and 15. Samples for the evaluation of serum ADAs were obtained preinjection, on study day 29, and at the follow-up visit on day 56.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Planned and enrolled participants in the phase 1a study

> “Approximately 9 to 15 participants with open-angle glaucoma are assigned into 3 sequential dose-levels and will receive ANX007 administered as single, IVT injections.”

Source: [ClinicalTrials.gov NCT03488550](https://clinicaltrials.gov/study/NCT03488550)

> “Sample sizes were determined by clinical and practical, rather than statistical, considerations.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

###### Safety and immunogenicity analysis population

> “Pooled data are reported by dose level of ANX007 by study and non-study eye, where applicable. Patients who received ≥ 1 injection of ANX007 were assessed for safety and immunogenicity endpoints. The incidences of treatment-emergent AEs were tabulated by system organ class and preferred term, as well as by ocular or systemic intensity, or Common Terminology Criteria for Adverse Events grade, and by relationship to ANX007.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

###### Completion of the phase 1a study

> “All 9 patients completed the study; there were no early terminations.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

###### Demographics of the phase 1a study by dose cohort

| Characteristic | ANX007 1.0 mg (n = 3) | ANX007 2.5 mg (n = 3) | ANX007 5.0 mg (n = 3) | Overall (n = 9) |
| --- | --- | --- | --- | --- |
| Age, mean (SD), yr | “66.3 (12.5)” | “70.7 (4.0)” | “72.7 (3.5)” | “69.9 (7.4)” |
| Age, median (min, max), yr | “66.0 (54, 79)” | “73.0 (66, 73)” | “73.0 (69, 76)” | “73.0 (54, 79)” |
| Male, n (%) | “1 (33.3)” | “3 (100.0)” | “2 (66.7)” | “6 (66.7)” |
| Female, n (%) | “2 (66.7)” | “0” | “1 (33.3)” | “3 (33.3)” |
| Black/African American, n (%) | “1 (33.3)” | “0” | “0” | “1 (11.1)” |
| Asian, n (%) | “0” | “2 (66.7)” | “0” | “2 (22.2)” |
| White, n (%) | “2 (66.7)” | “1 (33.3)” | “3 (100.0)” | “6 (66.7)” |
| Weight, mean (SD), kg | “105.2 (6.7)” | “83.7 (7.2)” | “82.2 (15.6)” | “90.3 (14.5)” |

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.5.8.2-2"></a>

###### Overall phase 1a study population

> “The majority of patients were male (n = 6, 66.7%) and White (n = 6, 66.7%), with a mean age (SD) of 69.9 (7.4) years (Table 1).”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### Serum pharmacokinetics and C1q after a single dose

> “Serum unbound ANX007 was not detected, and serum unbound C1q levels were unchanged over the period of the study.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

###### Adverse events in the phase 1a study by dose cohort

| n (%) | ANX007 1 mg (n = 3) | ANX007 2.5 mg (n = 3) | ANX007 5 mg (n = 3) | Overall (n = 9) |
| --- | --- | --- | --- | --- |
| Any TEAE | “3 (100.0)” | “3 (100.0)” | “3 (100.0)” | “9 (100.0)” |
| Ocular disorders | “3 (100.0)” | “3 (100.0)” | “2 (66.7)” | “8 (88.9)” |
| Infection | “0” | “0” | “1 (33.3)” | “1 (11.1)” |
| Treatment-related TEAE | “3 (100.0)” | “3 (100.0)” | “2 (66.7)” | “8 (88.9)” |
| Conjunctival hemorrhage | “0” | “2 (66.7)” | “0” | “2 (22.2)” |
| Conjunctival hyperemia | “3 (100.0)” | “3 (100.0)” | “2 (66.7)” | “8 (88.9)” |
| Eye irritation | “2 (66.7)” | “0” | “0” | “2 (22.2)” |

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.5.8.5-2"></a>

###### Ocular and systemic adverse events after a single dose

> “Eight ocular TEAEs were reported in the study eye, including ocular irritation, conjunctival hemorrhage, and conjunctival hyperemia, and 1 systemic TEAE was reported (sinusitis) which was not assessed to be related to ANX007 (Table 2). No ocular TEAEs were reported in the non-study eye for any patient. All AEs were mild in severity and resolved by the end of the study and there were no clinically significant laboratory results at any time during the on-therapy period.”
> “No dose-limiting toxicities were observed.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.5.8.5-3"></a>

###### Safety across both glaucoma studies

> “In both studies, no serious adverse events were observed, no non-ocular treatment-emergent adverse events (TEAEs) attributable to study drug were reported, and ocular TEAEs were mild.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

> “The studies showed that vonaprument was well-tolerated at all doses (1 mg, 2.5 mg and 5 mg)”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-3.1.5.8.5-4"></a>

###### Intraocular pressure after a single dose

> “Intraocular pressure returned to normal levels (defined as within 5 mm Hg of baseline or ≤ 21 mm Hg) at 30 minutes for all patients. Mean IOP measurements were within normal limits (≤ 21 mm Hg) at all time points (Table 3).”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

| Time point | ANX007 1 mg, mean (SD) | ANX007 2.5 mg, mean (SD) | ANX007 5 mg, mean (SD) |
| --- | --- | --- | --- |
| Baseline | “17.7 (1.15)” | “16.3 (3.06)” | “15.0 (2.65)” |
| 30 minutes postinjection | “19.3 (2.89)” | “17.3 (4.16)” | “18.0 (3.61)” |
| Day 2 | “16.3 (3.79)” | “10.7 (3.06)” | “13.3 (2.52)” |
| Day 29 | “18.3 (1.53)” | “17.0 (1.00)” | “15.0 (5.29)” |
| Day 56 | “15.3 (1.15)” | “14.0 (1.00)” | “14.3 (3.21)” |

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.5.8.5-5"></a>

###### Anti-drug antibodies after a single dose

> “No ADAs positivity was detected during the study at any ANX007 dose level at any of the timepoints assessed.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary: glaucoma population, small open-label cohorts, and serum-only pharmacodynamics

ANX007-GLA-01 was a first-in-human, open-label, single-dose escalation study in 9 participants with primary open-angle glaucoma (3 per dose cohort of 1.0, 2.5, and 5.0 mg), a population that differs from the geographic atrophy population of the phase 2 and phase 3 trials. The study had no masking and no control arm, follow-up lasted 8 weeks, and sample sizes were “determined by clinical and practical, rather than statistical, considerations”, with data presented descriptively. Aqueous humor was not sampled in this study, so pharmacokinetics and target engagement were assessed in serum only, where unbound ANX007 was not detected. The article states that there were no treatment-emergent adverse events after single injections, and in the same paragraph reports 8 ocular treatment-emergent adverse events and 1 systemic event, with all 9 participants (100.0%) having any treatment-emergent adverse event in its Table 2. The 5-mg dose was given in 100 μL, while the ongoing phase 3 ARCHER II trial administers 5 mg in a 25-microliter dose.

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/); [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
